The Science of Reversal: A Functional Medicine Thesis on Root-Cause Strategy for Reversing Type 2 Diabetes

1. Abstract / Executive Overview

Type 2 diabetes mellitus (T2DM) has long been approached as a lifelong, progressively worsening condition managed primarily through glucose-lowering medications. However, growing scientific evidence suggests that this perspective overlooks the underlying metabolic disturbances that drive the disease. Rather than being a disorder of glucose alone, T2DM reflects a broader breakdown in metabolic regulation involving insulin resistance, excess energy storage, chronic inflammation, mitochondrial dysfunction, and impaired cellular signaling across multiple organs. This review explores the emerging concept of metabolic reversal by examining T2DM through a root-cause lens grounded in functional and systems-based physiology. Drawing on evidence from nutritional science, metabolic research, and clinical intervention studies, the article highlights how targeted dietary changes, lifestyle restructuring, and metabolic reconditioning can restore insulin sensitivity, reduce ectopic fat accumulation in the liver and pancreas, and relieve stress on pancreatic β-cells. By shifting the focus from symptom control to physiological repair, this review reframes Type 2 diabetes as a dynamic and potentially reversible metabolic state. The findings presented support the growing recognition that meaningful, sustained improvements in metabolic health are achievable when the biological drivers of the disease are directly addressed.

Introduction:

2. Background & Clinical Context

Cover

- **Epidemiology of Type 2 Diabetes**

Type 2 Diabetes Mellitus (T2DM) represents a significant global health challenge, characterized by its increasing prevalence and profound impact on public health systems worldwide. The epidemiology of T2DM encompasses its distribution, determinants, and risk factors across various populations, which are critical for developing effective prevention and management strategies. The disease is fundamentally driven by insulin resistance and progressive beta-cell dysfunction, leading to chronic hyperglycemia. The epidemiology of T2DM encompasses its distribution, determinants, and risk factors across various populations, which are critical for developing effective prevention and management strategies. The disease is fundamentally driven by insulin resistance and progressive beta-cell dysfunction, leading to chronic hyperglycemia.

The global burden of T2DM has been rising dramatically over the past few decades, evolving into a noncommunicable epidemic primarily driven by rapid environmental and lifestyle changes. Projections indicate a continued increase in prevalence and mortality rates. For instance, global prevalence estimates for diabetes in adults aged 20-79 years were projected for 2019, with further projections for 2030 and 2045. By 2050, the estimated prevalence for all ages is expected to reach 10.23%, with mortality around 2.05 million, while for adults over 20 years, prevalence is projected to be 11.97% and mortality 1.9 million.



Region/Country	Number of studies	Diabetes prevalence (%)	Relative contribution (%)
Global	250+	10.5%	100%
United States	45	11.3%	9%
China	50	12.8%	27%
India	40	10.4%	16%
Australia	25	6.2%	2%
Europe (selected)	35	9.1%	12%

- **Current standard-of-care limitations**

Despite significant advances in the clinical management of Type 2 diabetes mellitus (T2DM), substantial limitations persist in achieving durable glycemic control and long-term metabolic stability for a large proportion of patients. Conventional care models rely heavily on pharmacological interventions and surrogate markers such as HbA1c to guide treatment decisions. While these approaches have improved short-term outcomes, they often fail to fully capture glycemic variability, address underlying metabolic drivers, or ensure sustained disease control. Consensus guidelines from leading professional bodies such as the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recognize the importance of weight management and comprehensive care alongside drug therapy; however, effective integration of these elements into long-term clinical practice remains inconsistent. As a result, many patients continue to experience suboptimal outcomes,

treatment escalation, and increasing healthcare burden despite access to modern therapies.

Key Limitations in Current Type 2 Diabetes Management

1. **Incomplete Glycemic Control Despite Treatment**
   A significant proportion of individuals with T2DM fail to achieve recommended glycemic targets, even with multiple therapeutic interventions. Reliance on HbA1c as the primary monitoring tool does not adequately reflect daily glucose fluctuations or metabolic instability, limiting its utility as a sole indicator of disease control.

2. **Constraints of Pharmacological Therapies**
   Although newer drug classes such as SGLT2 inhibitors and GLP-1 receptor agonists provide cardiovascular, renal, and metabolic benefits, their use is associated with potential adverse effects, contraindications, and patient-specific limitations. These factors can restrict their applicability, particularly in older adults and individuals with complex comorbidities.

3. **Challenges in Managing Older and High-Risk Populations**
   Older adults are frequently under-represented in clinical trials, resulting in uncertainty regarding the balance of risks and benefits of glucose-lowering therapies in this population. Treatment intensification and medication escalation require nuanced clinical judgment, which may not always be optimally applied in routine practice.

4. **Poor Long-Term Adherence to Treatment Plans**
   Patient adherence to both pharmacological therapy and recommended lifestyle modifications remains a major challenge. Non-adherence is influenced by multiple factors, including medication side effects, treatment complexity, perceived benefit, forgetfulness, and lack of sustained motivation, ultimately compromising clinical outcomes.



- **Disease progression despite pharmacological control**

Several clinical factors are associated with the progression of T2DM. A retrospective cohort study identified obesity, clinical characteristics, and genetic predictors for glycemic progression in Chinese patients with T2DM. Similarly, studies in a Ugandan population highlighted variability in progression rates, indicating that individual and population-specific factors play a role. The concept of "heterogeneity" in T2DM is crucial, as genetic, socioeconomic, and clinical features significantly influence disease development, progression, and response to therapy. This heterogeneity suggests that a "patient-centered approach" is essential for effective treatment.

Epigenetic modifications, such as DNA methylation, histone alterations, and non-coding RNA, are increasingly recognized for their critical role in T2DM onset and progression. Environmental factors and lifestyle choices interact with genetic predispositions to influence these epigenetic changes, contributing to insulin resistance and beta-cell dysfunction.

Despite the availability of a broad armamentarium of pharmacological agents, many patients with advanced T2DM continue to experience complications and premature mortality. This is partly due to the progressive nature of the disease and often due to delayed treatment intensification (clinical inertia) or suboptimal adherence to treatment regimens. Studies have shown that non-adherence to cardiometabolic medication, objectively assessed by LC-MS/MS in urine, is a frequent barrier to effective treatment.

3. Reframing Type 2 Diabetes: A Systems Biology Perspective

Break T2D into interconnected pathological domains:

3.1 Insulin Resistance as a Multi-Tissue Phenomenon

Insulin resistance in type 2 diabetes (T2DM) is a multi-tissue phenomenon that fundamentally involves the liver, skeletal muscle, and adipose tissue, each contributing distinctly to the systemic metabolic dysregulation characteristic of the disease. This widespread dysfunction often precedes the clinical diagnosis of T2DM and plays a critical role in its progression, even under pharmacological control.

- **Liver, skeletal muscle, adipose tissue**

In **skeletal muscle**, insulin resistance manifests as impaired glucose uptake. Normally, insulin stimulates glucose transporter type 4 (GLUT4) translocation to the cell surface, facilitating glucose entry into muscle cells for energy or storage as glycogen. In insulin-resistant states, this process is blunted, leading to reduced glucose utilization by muscles and contributing to hyperglycemia. Mitochondrial dysfunction, characterized by decreased mitochondrial content, size, and respiration rate, also plays a role in impaired oxidative phosphorylation within muscle cells, further exacerbating metabolic abnormalities. Ectopic fat deposition in skeletal muscle is an additional factor contributing to insulin resistance in this tissue.

The **liver** also plays a central role in insulin resistance. Under normal physiological conditions, insulin suppresses hepatic glucose production (HGP), primarily through inhibiting gluconeogenesis and glycogenolysis. In insulin-resistant livers, this suppressive effect is diminished, leading to increased and unregulated HGP, which significantly contributes to fasting and postprandial hyperglycemia. Like skeletal muscle, the liver can also accumulate ectopic fat, a condition known as non-alcoholic fatty liver disease (NAFLD), which is strongly associated with hepatic insulin resistance and T2DM progression.

Adipose tissue dysfunction is a critical component of multi-tissue insulin resistance and T2DM progression. Adipocytes, the primary cells of adipose tissue, undergo significant changes in T2DM. Adipocyte hypertrophy (enlargement) and atrophy, alongside increased fat storage, disrupt normal adipose tissue function. There is a decrease in GLUT4 expression and translocation in adipocytes, impairing glucose uptake. Mitochondrial dysfunction, similar to that in muscle, is also observed in adipose tissue, affecting energy production. Furthermore, brown adipocyte dysfunction, characterized by decreased β3-adrenergic receptors and blunted β-adrenergic responses, contributes to impaired thermogenesis and metabolic function.

- **Ectopic lipid accumulation**

Ectopic fat deposition plays a pivotal role in the pathogenesis of insulin resistance and type 2 diabetes mellitus (T2DM). This phenomenon involves the storage of triglyceride

(TG) droplets in non-adipose tissues, such as the liver, skeletal muscle, heart, and pancreas, which are not primarily designed for fat storage. This abnormal accumulation of lipids leads to cellular dysfunction, often referred to as lipotoxicity, which interferes with insulin signaling and contributes significantly to the development and progression of metabolic disorders.

The primary mechanism linking ectopic fat deposition to insulin resistance is the disruption of metabolic processes by intermediates of lipid metabolism, rather than the triglycerides themselves. These bioactive lipids, such as diacylglycerols (DAGs) and ceramides, can interfere with insulin signaling pathways within cells. For example, DAGs can activate protein kinase C (PKC) isoforms, which phosphorylate insulin receptor substrate-1 (IRS-1) on serine residues. This serine phosphorylation inhibits the normal tyrosine phosphorylation of IRS-1, effectively blocking the downstream cascade of insulin signaling, including the activation of Akt and the translocation of GLUT4 glucose transporters to the cell surface in muscle cells.

3.2 Mitochondrial & Metabolic Inflexibility

- **Reduced oxidative capacity**

Research indicates that specific defects in mitochondrial oxidative phosphorylation (OXPHOS) are present in type 2 diabetes mellitus (T2DM). For instance, studies on the rectus abdominis muscle from diabetic obese individuals revealed impaired mitochondrial OxPhos and supercomplex assembly. The capacity of individual complexes of the electron transport chain (ETC) can be measured using high-resolution respirometry, showing defects in substrate oxidation for complex I and complex II. These impairments can lead to an increased production of reactive oxygen species (ROS) and oxidative stress, further contributing to mitochondrial damage and cellular dysfunction



.

As illustrated in the diagram, an increase in Reactive Oxygen Species (ROS) and a decrease in antioxidant defense lead to oxidative stress. This oxidative stress, in turn, causes mitochondrial dysfunction and impaired ATP synthesis. The reduced ATP synthesis disrupts the insulin signaling pathway, leading to insulin resistance and ultimately hyperglycemia and Type 2 Diabetes.

3.3 Different Factors

Stress:

Chronic stress is known to contribute extremely to causing T2DM, influencing its etiology and management. This relation between stress and T2DM is multifaceted, incorporating complex interactions between neuroendocrine metabolics and immune systems.

The physiological stress response, often described as the "fight or flight" mechanism, involves the rapid release of counter-regulatory hormones such as cortisol and catecholamines (adrenaline and noradrenaline). These hormones are crucial for energy mobilization in healthy individuals, stimulating the liver to produce glucose (gluconeogenesis) and simultaneously making peripheral tissues, such as muscle and fat, resistant to insulin's actions. While adaptive in acute, short-term situations, this response becomes detrimental in the context of, leading to persistently elevated blood glucose levels and insulin resistance.

The hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic-adrenal-medullary (SAM) axis are key neuroendocrine pathways activated by stress. Hyperactivity of the HPA axis, often seen in chronic hyperglycaemic states, leads to increased cortisol

secretion. Cortisol, by promoting gluconeogenesis and decreasing insulin sensitivity, directly contributes to hyperglycaemia. Simultaneously, the SAM axis activation releases catecholamines, further elevating blood glucose. This complex interplay is illustrated in the diagram below, showing how hyperglycaemia in T2DM can lead to the activation of the HPA and SAM axes, as well as the immune system, and the production of cytokines (e.g., IL-1β, IL-6, TNF-α), ultimately promoting insulin resistance and contributing to depressive symptoms.

Epidemiological studies further support the link between psychological stress and T2DM. A 35-year follow-up study of middle-aged Swedish men found a positive association between self-perceived stress at baseline and the incidence of diagnosed diabetes.

Endotoxins

Endotoxins, particularly lipopolysaccharides (LPS) from Gram-negative bacteria, are increasingly recognized as significant contributors to the pathogenesis of (T2DM) through their role in inducing chronic low-grade inflammation, often referred to as metabolic endotoxemia. Metabolic endotoxemia is characterized by elevated levels of circulating LPS in the blood, typically in picogram per milliliter ranges, which is considerably lower than the nanogram per milliliter levels seen in sepsis, but sufficient to trigger persistent inflammatory responses 3. This chronic exposure to bacterial products from the gut can significantly impair insulin signalling and contribute to insulin resistance, a central feature of T2DM.

The gut microbiota plays a crucial role in this process. Dysbiosis, an imbalance in the composition and function of the gut microbial community, is frequently observed in individuals with T2DM. This dysbiosis, often driven by diets high in saturated fats and low in fiber, can compromise the integrity of the intestinal mucosal barrier, leading to increased intestinal permeability. When the gut barrier is weakened, LPS and other bacterial components can translocate from the intestinal lumen into the bloodstream, initiating metabolic endotoxemia.

Once in the circulation, LPS activates the innate immune system primarily through Toll-like receptor 4 (TLR4) 4. This activation triggers a cascade of inflammatory signalling pathways, including the c-Jun N-terminal kinase (JNK) pathway and NF-κB, leading to the production and release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). These cytokines are known to interfere directly with insulin signalling pathways, particularly by inducing inhibitory serine phosphorylation of insulin receptor substrate-1 (IRS-1), thereby disrupting glucose uptake and utilization in insulin-sensitive tissues like muscle and liver. This mechanism directly contributes to systemic insulin resistance, a hallmark of T2DM.

Research indicates that individuals with T2DM consistently exhibit higher circulating endotoxin levels compared to healthy controls. For example, a population-based study in China found that elevated blood endotoxin levels were associated with an increased risk of T2DM 26. Similarly, studies involving patients with T2DM have shown a direct

correlation between poor short-term glycaemic control and impaired intestinal mucosal barrier function, leading to higher blood endotoxin levels 28.

High-carb Indian diet and Nutrient deficiency.

The pervasive consumption of high-carbohydrate diets in India, coupled with prevalent micronutrient deficiencies, presents a significant risk factor for the development and progression of T2DM. Indian dietary patterns are characterized by high intakes of low-quality carbohydrates, such as white rice and highly milled whole grains, along with significant levels of added sugar and saturated fats. This dietary composition, compounded by rapid dietary transitions driven by urbanization and economic growth, contributes to an alarming rise in cardiometabolic diseases, including T2DM.

A recent study involving 18,090 Indian adults revealed that average daily carbohydrate intake is 275 grams, representing approximately 56.4% of total energy intake. This proportion is consistent across various states in India, ranging from 51.0% in Himachal Pradesh to 65.7% in Mizoram. Notably, while dietary fat intake constitutes around 25.5% of energy and protein intake is about 13.9%, a substantial portion of carbohydrates comes from refined grains and added sugars. For instance, total cereals contribute to 35.8% of daily energy intake, with white rice alone accounting for 19.3%. This high intake of refined carbohydrates is associated with increased abdominal obesity and higher fasting plasma glucose levels. The metabolic implications of such diets are critical, as high glycaemic index foods, common in Indian diets, can lead to higher glycaemic and insulinemic responses, promoting insulin resistance and beta-cell exhaustion, which are central to T2DM pathophysiology.

Beyond macronutrient composition, micronutrient deficiencies are a widespread health challenge in India, impacting millions and contributing to various health issues, including T2DM. These deficiencies, often termed "hidden hunger," occur even among individuals with adequate caloric intake but low nutrient density from processed foods. Essential vitamins and minerals such as iron, zinc, vitamin A, iodine, vitamin D, magnesium, and calcium are frequently inadequate in the Indian diet.

The interaction between high-carbohydrate diets and micronutrient deficiencies creates a synergistic effect that exacerbates T2DM risk. Insulin resistance, a hallmark of T2DM, can be exacerbated by both poor macronutrient quality and specific micronutrient deficits 1516. For instance, diets rich in refined carbohydrates cause rapid blood glucose spikes, requiring higher insulin production and increasing the burden on pancreatic beta-cells 3. Over time, this leads to Beta cell dysfunction and relative insulin deficiency. When coupled with deficiencies in micronutrients like magnesium and vitamin D, which are critical for insulin signalling pathways and glucose metabolism, the risk of developing T2DM is significantly amplified 11.

Harmful blue light:

Exposure to blue light during nighttime causes a significant change in circadian rhythms, which can influence metabolic health and potentially increase the risk of T2DM. The Human circadian system is primarily regulated by the suprachiasmatic nucleus (SCN) in the hypothalamus, which is profoundly affected by light exposure, especially blue light. Intrinsically photosensitive retinal ganglion cells (ipRGCs) are critical photoreceptors that detect blue light and transmit signals to the SCN, influencing melatonin secretion and sleep cycle disruption. Disruption of this light-dark cycle, particularly through exposure to (artificial light at night) rich in blue wavelengths, can suppress melatonin production and misalign the body's internal clock with the external environment.

Furthermore, outdoor light at night (LAN), which often contains blue light components from modern lighting, has been prospectively linked to T2DM incidence, with genetic predisposition potentially interacting with this environmental factor. A large prospective study involving 471,686 participants from the UK Biobank also investigated the relationship between blue light exposure and T2DM incidence, suggesting a connection that could be influenced by factors such as sleep duration, physical activity, and outdoor activity time.

The mechanisms by which blue light and circadian disruption contribute to T2DM are multifaceted. Circadian rhythm disruption can lead to insulin resistance, a hallmark of T2DM. Insulin resistance refers to the failure of tissues to respond adequately to insulin, leading to elevated blood glucose levels.

Seed oils as a causative agent.

The increasing cases of T2DM is a major public health concern. Recent research by experts such as Dr. Cate Shanahan, Ben Greenfield and Chris Masterjohn have shed light on the potential role of industrial seed oils in the development of Diabetes.These Oils contain high amounts of Omega-6-fatty acids and are widely used in the food industry. Understanding the relation between seed oils and health/metabolic dysfunction is important for addressing Type-2-Diabetes. Industrial seed oils are predominantly composed of omega-6 fats, which can be detrimental when consumed in excess. Excessive consumption of industrial seed oils, which are high in omega-6 fats, poses a significant risk to metabolic health. These fats damage cell membranes, the "cellophane wrapper" compromising their integrity. This structural alteration hinders cellular communication, a process vital for proper cellular function. This breakdown in communication is a critical initial step leading to insulin resistance, a central characteristic of Type 2 diabetes. Furthermore, the excessive consumption of omega-6 fatty acids from seed oils has been linked to impaired insulin signaling. Insulin is a critical hormone for regulating blood glucose levels, and its proper function is dependent on the signaling pathways within the cells. The disruption of these pathways by omega-6 fats hinders the cells' ability to respond to insulin effectively.

As a result, glucose accumulates in the bloodstream, leading to elevated blood sugar levels and, over time, the onset of Type 2 diabetes. Seed oils are a critical factor linking to diabetes due to their role in promoting inflammation and oxidative stress. The

omega-6 fatty acids in these oils are precursors to pro-inflammatory molecules, which intensify the chronic, low-grade inflammation commonly observed in Type 2 diabetes. Furthermore, the oxidative stress induced by these fats damages cellular components, disrupting normal metabolic function. This synergy of inflammation and oxidative stress negatively impacts both insulin sensitivity and glucose metabolism. Mitochondria, the energy powerhouses of cells, are also adversely affected by the high intake of omega-6 fatty acids. Healthy mitochondrial function is crucial for efficient energy production and metabolism. However, under the influence of omega-6 fats, mitochondrial efficiency declines, leading to reduced energy availability and metabolic dysfunction. This disruption contributes to insulin resistance and hampers the body's ability to maintain normal glucose levels.

Insulin resistance, the body's impaired ability to utilize insulin for effective glucose control, is a consequence of multiple cellular dysfunctions. These include damage to cell membranes, compromised insulin signaling, heightened oxidative stress, chronic inflammation, and mitochondrial disruption. The development of this resistance significantly elevates the risk of progressing to Type 2 diabetes. In summary, the scientific evidence strongly indicates that industrial seed oils contribute to the development of Type 2 diabetes through various underlying biological mechanisms. A deeper understanding of these processes allows for informed dietary adjustments to potentially lower the risk of this chronic disease. Prioritizing metabolic health and diabetes prevention can involve a crucial step: reducing the consumption of omega-6-rich seed oils and selecting healthier fat alternatives.

Metabolic Reversal of Type-2-Diabetes.

The Metabolic Reversal of type 2 diabetes represents a paradigm shift in the understanding and management of this chronic condition, moving from lifelong pharmacological control to the possibility of disease remission through targeted interventions that address its underlying pathophysiology. This transformation is grounded in robust scientific evidence demonstrating that diabetes is not an inevitably progressive disorder but rather a reversible state driven by excess ectopic fat accumulation in key metabolic organs, primarily the liver and pancreas, which disrupts insulin sensitivity and β-cell function.

The central mechanism underpinning this reversibility is the removal of lipid overload from these tissues via sustained negative energy balance, achieved through dietary restrictions, bariatric surgery, or structured lifestyle modification. Landmark studies have shown that even short-term caloric restrictions can rapidly normalise fasting glucose levels within days, preceding significant weight loss, by suppressing hepatic glucose production through reduced pyruvate carboxylase activity and restoring first-phase insulin secretion.

Functional medicine for the reversal of diabetes

Functional medicine offers a paradigm-shifting approach to the reversal of (T2D) by targeting the root-cause mechanisms of metabolic dysfunction rather than merely managing hyperglycemia through pharmacological suppression. This model emphasizes personalized, systems-oriented interventions that restore physiological balance, with compelling evidence demonstrating complete remission of T2D in appropriately selected individuals. The foundational principle is that T2D arises from ectopic fat accumulation in insulin-sensitive organs, particularly the liver and pancreas, driven by chronic caloric excess, sedentary behavior, and genetic susceptibility. Functional medicine leverages this understanding to implement multimodal strategies centered on sustained negative energy balance, dietary reprogramming, gut health optimization, and metabolic resilience restoration.

The **twin cycle hypothesis**, validated across multiple clinical studies, provides the mechanistic framework for the success of functional medicine in reversing type 2 diabetes (T2D). It posits that intrahepatic lipid (IHL) accumulation induces hepatic insulin resistance, leading to unregulated glucose production. At the same time, intrapancreatic triglyceride (IPTG) deposition impairs β-cell function by disrupting glucose-stimulated insulin secretion. Critically, these processes are reversible: removal of excess fat from both organs via substantial weight loss restores insulin sensitivity and β-cell responsiveness. The DiRECT trial demonstrated that a structured very-low-calorie diet (VLCD) of approximately 800 kcal/day led to remission in 46% of participants at one year, with remission rates directly correlated to weight loss magnitude. Individuals who lost >15 kg achieved an 86% remission rate. These outcomes underscore the dose-dependent relationship between fat mass reduction and metabolic recovery, reinforcing the centrality of energy deficit in functional medicine protocols.

These findings are supported by the twin cycle hypothesis, which posits that intracellular triglyceride accumulation in hepatocytes induces hepatic insulin resistance, leading to uncontrolled gluconeogenesis while concurrent fat deposition in pancreatic β-cells impairs their ability to secrete insulin in response to glucose, creating a self-perpetuating cycle of hyperglycemia.

A critical determinant of successful metabolic reversal is the preservation of β-cell function capacity, particularly indicated by measurable C-peptide levels, which reflect endogenous insulin production. Patients with shorter duration of diabetes have higher baseline C-peptide concentration and greater that 10% reduction of weight show significantly higher rates of remission, underscoring the importance of early intervention before irreversible β-cell dedifferentiation or apoptosis occurs. Intensive lifestyle therapy, including very low-calorie diets (VLCD) providing approximately 800 kcal/day, has been shown to induce remission in up to 60% of individuals with recent onset of type 2 diabetes, with durability maintained over several years if weight regain is prevented. Similarly, carbohydrate-restricted and ketogenic dietary patterns have demonstrated efficacy in improving glycemic control and reducing medication dependence. Emerging digital health technologies incorporating continuous and personalized nutrition algorithms further enhance precision in guiding metabolic

recovery, allowing for real-time feedback and dynamic adjustment of dietary and behavioral strategies.
Beyond nutritional and surgical approaches, novel pharmacotherapies targeting specific nodes in the insulin signaling cascade and mitochondrial metabolism offer additional avenues for promoting metabolic restoration. For example, agents that activate sirtuins, NAD+-dependent deacetylases involved in oxidative stress regulation and metabolic flexibility, such as resveratrol, have shown promise in preclinical models by enhancing insulin sensitivity and protecting β-cell function in high-fat diet-induced diabetic mice. Furthermore, metabolomic profiling of patients achieving remission has identified distinct biomarker signatures, including shifts in branched-chain amino acids, acylcarnitines, and phospholipid species, which may serve as predictive tools for treatment response and guide individualized therapy development. Collectively, these advances affirm that type 2 diabetes remission is a clinically attainable goal when interventions are aligned with the core pathophysiological mechanisms of the disease, emphasizing the need for a proactive, multidisciplinary approach that integrates nutritional science, endocrinology, surgery, and behavioral psychology to achieve durable metabolic health.

Functional ingredients involved in the remission of type-2-diabetes.

The functional ingredients involved in the remission of (T2D) operate through targeted modulation of metabolic pathways, oxidative stress, and insulin signaling, aligning with a root-cause therapeutic framework grounded in clinical and molecular evidence. These bioactive compounds enhance metabolic flexibility, reduce ectopic fat accumulation, and restore β-cell function by engaging key regulatory nodes such as sirtuins, AMP-activated protein kinase (AMPK), and mitochondrial antioxidant systems. Their efficacy is supported by preclinical models and mechanistic studies, positioning them as integral components of functional medicine strategies aimed at achieving durable T2D remission.

Resveratrol, a natural polyphenol found in grapes and red wine, has emerged as a potent modulator of insulin sensitivity and oxidative stress. It activates SIRT1, an NAD+-dependent deacetylase that plays a central role in energy homeostasis and cellular stress resistance. In high-fat diet-fed mice, resveratrol treatment significantly reduced fasting blood glucose, plasma triglycerides, and insulin resistance while decreasing intracellular reactive oxygen species (ROS) levels. This effect is mediated through the AMPK-SIRT1-FoxO1 signaling axis, where SIRT1 deacetylates FoxO1 to regulate genes involved in gluconeogenesis, lipid metabolism, and antioxidant defense. By enhancing this pathway, resveratrol improves hepatic insulin sensitivity and protects pancreatic β-cells from glucolipotoxicity, a critical mechanism in reversing T2D pathophysiology.

Honokiol (HNK), derived from *Magnolia officinalis*, exhibits similar sirtuin-targeting properties and demonstrates protective effects against metabolic dysfunction. Although direct human trials are limited, preclinical data suggest HNK enhances mitochondrial function and reduces inflammation via SIRT3 activation. SIRT3, localized in mitochondria, regulates superoxide dismutase 2 (SOD2) and glutathione peroxidase 4 (Gpx4) by deacetylation, thereby maintaining redox balance and preventing oxidative damage to metabolic tissues. Given that mitochondrial oxidative stress is a hallmark of insulin resistance, compounds like honokiol that bolster endogenous antioxidant defenses represent promising adjuncts to dietary and lifestyle interventions for T2D reversal.

Melatonin, primarily known for circadian regulation, also exerts significant metabolic benefits through interaction with the SIRT1 pathway. It modulates the AMPK-SIRT1-FoxO1 network, improving insulin sensitivity and reducing hepatic glucose output. Additionally, melatonin's antioxidant properties mitigate ROS-induced β-cell dysfunction, preserving insulin secretion capacity during early-stage T2D when functional recovery remains feasible. Circadian alignment supported by melatonin may further optimize metabolic responses to timed feeding and caloric restriction, key pillars of remission protocols.

Other investigational compounds include **synthetic SIRT1 activators** such as SRT1720, which have demonstrated robust improvements in glucose tolerance and insulin action in animal models of obesity and diabetes. While not yet approved for clinical use, these agents validate the therapeutic potential of targeting sirtuin pathways to reverse metabolic disease progression.



Beyond direct supplementation, endogenous upregulation of sirtuin activity can be achieved through nutritional ketosis and time-restricted eating, both of which increase

NAD+ availability, the essential cofactor for sirtuin function. Low-carbohydrate and very-low-calorie diets (VLCDs) induce a negative energy balance that rapidly depletes intrahepatic and intrapancreatic triglycerides, leading to normalized hepatic insulin sensitivity and restored first-phase insulin secretion within days. This physiological reset underpins the success of structured remission programs such as those tested in the DiRECT trial, where nearly half of participants achieved remission after one year on a VLCD regimen.

Metabolomic analyses further identify circulating biomarkers associated with successful remission, including reductions in branched-chain amino acids, ceramides, and specific acylcarnitine molecules linked to mitochondrial inefficiency and lipotoxicity. The modulation of these metabolites by functional ingredients underscores their role in reestablishing metabolic health beyond glycemic control alone.

Mineral & Vitamins Adaptogens:

Chromium Picolinate:

Multiple systematic reviews and meta-analyses have investigated the effects of chromium supplementation, particularly CrPic, on glycaemic control in T2DM patients. A pooled analysis of 28 studies indicated that chromium supplementation could impact clinically relevant metabolic biomarkers in T2DM patients. Another systematic review and meta-analysis of randomized controlled trials (RCTs) found that chromium supplementation improved glycaemic control indices in patients with T2DM. Specifically, chromium has been shown to reduce fasting blood glucose (FBG), glycated haemoglobin (HbA1c), and insulin levels, while also improving insulin sensitivity as measured by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). HbA1c is a crucial long-term indicator of glycaemic control, reflecting average blood glucose levels over the preceding 2-3 months. The rate of non-enzymatic glycation of haemoglobin, which forms HbA1c, is proportional to ambient glucose concentration.

For instance, an 8-week randomized clinical trial involving 52 T2DM patients demonstrated that daily supplementation with 400 µg of CrPic significantly improved glycaemic status and lipid profiles 1. Similarly, a randomized, double-blinded, placebo-controlled study with 60 T2DM subjects showed the efficacy of 200 µg/day chromium picolinate on glycaemic control 15. The mechanistic basis for CrPic's action is believed to involve its role as an insulin enhancer, increasing glucose tolerance by potentizing insulin's role in the cell 14. It is thought to improve insulin sensitivity by enhancing insulin receptor activity and modulating glucose metabolism pathways. Beyond glycaemic control, chromium supplementation has also been evaluated for its effects on other cardiometabolic parameters and complications associated with T2DM. A systematic review and dose-response meta-analysis of RCTs showed beneficial effects of chromium supplementation on blood pressure, body mass index (BMI), liver function enzymes, and malondialdehyde (MDA) in T2DM patients. An *in vivo* study in Wistar rats found that chromium mitigated iron-induced glucose metabolism disorder via

the PI3K/Akt/Bcl-2 signalling pathway. The PI3K-Akt pathway is critical in insulin action, promoting glucose uptake and energy storage.

Vanadium:

Vanadium compounds have been extensively investigated for their potential in the management of Mellitus (T2DM) due to their insulin-mimetic and insulin-enhancing properties. T2DM is a chronic metabolic disorder characterized by insulin resistance and impaired glucose homeostasis, often leading to systemic complications 89. The pathophysiology of T2DM involves a complex interplay of insulin resistance in tissues like muscle and liver, and progressive pancreatic beta-cell failure.

Vanadium's role as an insulin mimetic agent has been recognized since the 1970s. These compounds are believed to exert their therapeutic effects by influencing the insulin signalling pathway 7. Studies suggest that vanadium can potentiate insulin action by inhibiting protein tyrosine phosphatases (PTPs), which are enzymes that dephosphorylate and inactivate insulin receptors and their substrates. By inhibiting PTP-1B, a key PTP implicated in insulin resistance, vanadium compounds can maintain the phosphorylation state of insulin signalling proteins, thereby enhancing insulin sensitivity and glucose uptake. This mechanism is particularly relevant as PTP-1B is often overexpressed in patients with diabetes and obesity. The structural similarity between vanadate (V in the +5 oxidized state) and phosphate allows vanadate to act as a pan-inhibitor of PTPs.

Research has demonstrated that vanadium compounds can normalize glucose and blood lipid parameters in animal models of T2DM. For instance, vanadyl sulphate (VS) has been shown to possess effective hypoglycaemic properties and pleiotropic metabolic benefits in animal and human studies.

Alpha-Lipoic Acid (ALA): A master antioxidant that kills free radicals and improves insulin sensitivity.

Alpha-lipoic acid (ALA), an organosulfur compound synthesized endogenously and found in certain foods, has emerged as a molecule of significant interest for the management of Mellitus (T2DM) due to its potent antioxidant, anti-inflammatory, and insulin-sensitizing properties.

ALA and its reduced form, dihydrolipoic acid (DHLA), form a redox couple that enables them to scavenge various reactive oxygen species (ROS), chelate metals, and regenerate other antioxidants like vitamins C and E 4589. This antioxidant capacity is crucial because T2DM is associated with increased oxidative stress, which contributes to insulin resistance and the development of complications 76.

ALA enhances insulin sensitivity, a core defect in T2DM where target tissues like muscle and liver fail to respond adequately to insulin's signals 2106. Research indicates that ALA can improve glucose utilization and reduce insulin resistance 2109. Studies in high-fat diet and streptozotocin-induced type 2 diabetic rats showed that ALA improved insulin resistance and alleviated cognitive impairment, suggesting a cerebral insulin-sensitizing effect 10.

Vitamin C: Essential for reducing oxidative stress often found in diabetic patients.

Vitamin C, also known as ascorbic acid, is an essential water-soluble micronutrient with potent antioxidant properties that has attracted significant attention for its potential role in the management of Type 2 Diabetes Mellitus (T2DM).

Vitamin C acts as a critical scavenger of reactive oxygen species (ROS), protecting important biomolecules from oxidative damage. The chronic hyperglycaemic state in T2DM leads to an increased production of ROS, causing oxidative stress that contributes to insulin resistance and pancreatic beta-cell dysfunction. By reducing oxidative stress, vitamin C helps maintain cellular integrity and function.

Due to its structural resemblance to glucose, vitamin C can compete with glucose in non-enzymatic glycosylation reactions. This process, where glucose reacts with proteins to form advanced glycation end products, is a major contributor to microvascular and macrovascular complications in T2DM. By reducing AGE formation, vitamin C may mitigate vascular damage and improve endothelial function.

Meta-analyses of randomized controlled trials (RCTs) indicate that vitamin C supplementation can have favourable effects on glycaemic control markers, including fasting blood glucose (FBG) and glycated haemoglobin (HbA1c). For example, some studies reported significant reductions in HbA1c, FBG, and post-prandial blood glucose levels with vitamin C supplementation. A systematic review and meta-analysis of 23 RCTs found that vitamin C supplementation significantly decreased both FBG and HbA1c, particularly in studies where the intervention duration was ≥8 weeks, and the dosage was ≥500 mg/day.

Magnesium - 400-600 mg of elemental magnesium every day. For more info, scroll to the bottom.

Magnesium plays a crucial role in glucose metabolism and insulin sensitivity, with growing evidence suggesting its importance in the control and management of (T2DM). Hypoglycaemia, or low magnesium levels, is frequently observed in individuals with T2DM and is associated with poorer glycaemic control and an increased risk of diabetic complications.

Multiple studies have investigated the association between magnesium levels and T2DM. A meta-analysis examining the effects of oral magnesium supplementation on glycaemic control in T2DM patients revealed a dose-response relationship. Another study found that higher magnesium intake significantly reduced the risk of impaired

glucose and insulin metabolism and progression from prediabetes to diabetes in middle-aged Americans over 7 years.

The prevalence of hypomagnesemia in T2DM patients is substantial, with some studies reporting it in approximately one-third of patients. The severity of hypomagnesemia often correlates with the degree of glycemic control and is linked to the development of T2DM-associated complications, including diabetic nephropathy, neuropathy, and retinopathy. Renal magnesium wasting, exacerbated by insulin resistance and hyperglycemia-induced osmotic diuresis, is a primary cause of these conditions.

Herbal Adaptogens:

Gymnema Sylvestre: Known as the "sugar destroyer," it helps regenerate beta cells and blocks sugar receptors on the tongue.

Gymnema sylvestre, commonly known as Gurmar (“sugar destroyer”), is a perennial woody climber widely used in Ayurveda for the management of diabetes. For centuries, it has been valued for its ability to reduce sweet taste perception and improve glycaemic control. Modern pharmacological and clinical studies now support several of its traditional claims, making it a promising adjunct therapy in Type 2 Diabetes Mellitus (T2DM).

Gymnema sylvestre exerts its antidiabetic effects through a multi-targeted and synergistic mechanism, acting at the levels of taste perception, intestinal glucose absorption, pancreatic β-cell function, peripheral insulin sensitivity, and hepatic glucose metabolism. This pleiotropic mode of action makes it particularly relevant for the management of Type 2 Diabetes Mellitus (T2DM), which is characterized by insulin resistance, β-cell dysfunction, and dysregulated glucose homeostasis.

At the oral and gastrointestinal level, gymnemic acids, structurally analogous to glucose, competitively bind to sweet taste receptors (T1R2/T1R3) on the tongue, transiently suppressing the perception of sweetness. This sensory modulation reduces sugar cravings and the intake of high-glycemic foods. In the intestine, gymnemic acids interact with glucose transporters on the intestinal epithelium, particularly sodium glucose co-transporter 1 (SGLT1), thereby inhibiting glucose absorption and attenuating postprandial hyperglycaemia.

At the pancreatic level, *Gymnema sylvestre* enhances insulin secretion by stimulating residual pancreatic β-cells. Preclinical and clinical studies suggest that gymnemic acids may promote β-cell recovery by increasing cell membrane permeability to calcium ions, which triggers insulin exocytosis. Additionally, long-term supplementation has been associated with partial regeneration or preservation of β-cell mass, contributing to improved endogenous insulin availability in early and moderate stages of T2DM.

At the hepatic level, *Gymnema sylvestre* modulates glucose metabolism by suppressing hepatic gluconeogenesis and promoting glycogen synthesis. This dual action results in improved fasting blood glucose control and reduced hepatic glucose output. The herb

has also been shown to influence key enzymes involved in carbohydrate metabolism, further contributing to metabolic homeostasis.

Berberine:

Berberine has a beneficial effect on lipid metabolism, cardiovascular functions and neuroprotection indicates its potential in preventing and treating T2DM complications. Studies have demonstrated that berberine enhances hepatic glycogen synthesis both in vivo and in vitro, as observed in palmitic acid- and dexamethasone-treated HepG2 cells, liver tissues of db/db mice, and streptozotocin-induced diabetic C57BL/6 mice. Glycogen synthase kinase 3 beta (GSK3β), a widely expressed serine/threonine protein kinase, inhibits glycogen synthesis by phosphorylating and inactivating glycogen synthase (GS). Berberine has been shown to promote the phosphorylation of GSK3β via modulation of relevant signalling pathways, thereby enhancing glycogen synthesis. In fructose-induced diabetic mice, berberine increased GSK3β phosphorylation and stimulated hepatic glycogen deposition. Similar effects were observed in streptozotocin-induced and high-fat diet (HFD)-fed diabetic mice, where berberine upregulated GSK3β phosphorylation and raised hepatic glycogen content. Berberine treatment increased GK expression and glycogen levels in high-glucose-induced insulin-resistant AML12 and HuH7 hepatocyte models. Additionally, berberine can reshape the gut microbiome, promoting the proliferation of short-chain fatty acid (SCFA)-producing bacteria, and subsequently stimulating GLP-1 secretion by activating the GPR41 and GPR43 receptors on L cells, thereby indirectly enhancing the secretion of GLP-1. It is not difficult to understand that the induction of GLP-1 secretion by berberine is critical for maintaining blood glucose stability.

Momordica Charantia (Bitter Melon): Contains insulin-like compounds that lower blood glucose.

Bitter melon contains large amounts of vitamins C, A, E, B1, B2, and B3, as well as vitamin B9 (folate), making this vegetable a healthful addition to any diet. Regarding caloric content, the values for the leaves, fruit, and seeds are approximately 213, 242, and 177 Kcals per 100 g. Bitter melon is also rich in many minerals including potassium (K), calcium (Ca), zinc (Zn), magnesium (Mg), phosphorus (P), and iron (Fe), and is an excellent source of dietary fiber.

M. charantia contains several functional components such as polysaccharides, protein/peptides, terpenoids, saponins, alkaloids, flavonoids, and other bioactive components. Several bioactive compounds in *M. charantia,* including polypeptides, glycosides, sterols, and alkaloids, have demonstrated antidiabetic effects, with charantin, polypeptide p, and vicine being the main components responsible for hypoglycemic effects.

The current study's findings on *M. charantia* and metformin showed a triglyceride reduction of about 16%. In a different study, liver lipid measures in hamsters given diets rich in cholesterol and low in cholesterol are improved by extracts from bitter melon (Momordica charantia). In contrast to normal rats, the SD rats in this study displayed

elevated amounts of oxidative free radicals, including LPO and NO, in a variety of homogenates, including the liver, kidney, muscle, and pancreas. Both normal and SD animals' levels of free radicals (LPO and NO) dropped after receiving MCE treatment. The SD group in the current study had lower levels of SOD and glutathione. The SD rats' levels of SOD and GSH increased after receiving MCE treatment.

Aqueous extract can improve the protein expression of IRS-1 in liver tissue and GLUT4 in skeletal muscle to enhance glucose utilization in HFD-induced T2DM KK/HI mice, but not in STZ-induced T1DM ICR mice

Another study suggests that the water extract of bitter gourd stimulates GLP-1 and insulin secretion in mice, and the hypoglycemic effect can be reversed by a GLP-1 receptor antagonist. Subcutaneous injection with protein extract from MC fruit pulp can also lower plasma glucose and elevate insulin concentration via both insulin secretagogue and insulinomimetic activities, and this is further proved through pancreatic perfusion in situ.

Syzygium cumini (Jamun Seeds): Traditionally used to prevent the conversion of starch into sugar.

The Jamun tree is a valuable medicinal plant of the *Myrtaceae* family that has long been utilized in Indian and international traditional medicine. This is an essential medicinal plant used in Pakistani, Indian, Sri Lankan, and Bangladeshi health care systems that has been used to cure a variety of ailments in the past.

Certain flavonoids and other phenolic compounds from Jamun have been found to exhibit bioactive potentials. The pharmacological properties of Jamun are due to the rich contents of terpenoids, tannins, anthocyanins, flavonoids, and other phenolic compounds, which are among the chemical ingredients found in it. Anthocyanins, glucosides, ellagic acid, isoquercetin, kaempferol, and myricetin are among the substances found in the Jamun tree. The abundance of bioactive substances in Jamun roots, barks, leaves, and roots, also including tannins, phenols, lipids, alkaloids, and flavonoids, contributes to an enormous potential source of health-beneficial medicine and nutrition. The active presence of these compounds sustains pharmacological actions such as antioxidant, antibacterial, antidiabetic, central nervous system (CNS) activity, chemoprevention, anti-inflammatory, anti-allergic, and hepatoprotective characteristics in human health and metabolism.

Scientific study has shown that bioactivity-based fractionation and purification of the methanol extract of SC seed (SCME) led to the isolation of Vitalboside A (VBA) as a bioactive phytochemical. 5 The SCME and isolated VBA selectively inhibited protein tyrosine phosphatase (PTP1B) with 83% and 56% inhibition of PTP1B at 1 and 1.6 μm, respectively, in an in vitro assay. It has been postulated that VBA inhibits PTP1B via an allosteric mechanism, which was later confirmed by docking studies. The study also showed that both SCME and VBA demonstrated insulin-stimulated glucose uptake in 3T3- L1 and L6 cells at 1 μg/ml concentration.

methanolic extract of SC seed and its isolated active constituent, VBA exhibited 56% and 52% inhibition of PPAR-2 transactivation at 1 µg/mL and 1.6 µM concentration, respectively compared to GW9662 (10 µM) that showed 80% inhibition of PPAR-2. 5 This study also linked partial PPAR agonism of SCME and VBA to reduction in lipid accumulation in 3T3-L1 adipocytes with enhanced adiponectin secretion. Thus, it appears that SC methanolic seed extract with partial PPAR agonist activity may be useful as an insulin sensitizer for the management of type 2 diabetes.

Fenugreek Seeds & Cinnamon: Slows carbohydrate absorption and improves the body's response to insulin.

Fenugreek is a commonly used herb for the management of T2DM. The antidiabetic effect of fenugreek is associated with different mechanisms of action. In an in vitro study, Fenugreek seed extract inhibited alpha-amylase activity in a dose-dependent manner. Suppression of starch digestion and absorption induced by fenugreek seed extract was confirmed in normal rats in the same study. The hypoglycaemic effect of fenugreek is also associated with the inhibition of glucose uptake. Fenugreek seed extract inhibited intestinal sodium-dependent glucose uptake in vitro in rabbit intestinal brush border membrane vesicles.

A secondary mechanism by which fenugreek may regulate plasma glucose levels is by delaying gastric emptying and slowing down the rate of post-prandial glucose absorption due to its high soluble fiber content. It has been shown that fenugreek can also regulate the activity of key regulatory gluconeogenic enzymes. In streptozotocin (STZ)-induced diabetic rats, administration of Fenugreek seed extract decreased liver glucose-6-phosphatase activity, thus suppressing hepatic gluconeogenesis. Treatment of alloxan-induced diabetic rats with fenugreek whole seed powder also reduced high renal and hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase values to normal levels.

Scientific evidence indicates that **cinnamon** administration has therapeutic effects, such as antidiabetic and insulin-sensitizing activity through several mechanisms of action. It has been reported that in an in vitro model, *C. zeylanicum* bark extract can inhibit intestinal sucrase, pancreatic α-amylase, and α-glucosidase activities, and thus reduce carbohydrate digestion and absorption. Inhibition of pancreatic α-amylase activity was also observed in diabetic rats treated with *C. zeylanicum*. Cinnamaldehyde (from *C. zeylanicum*) reduced the activity of phosphoenolpyruvate carboxykinase (PEPCK) and normalized PEPCK messenger RNA (mRNA) levels in the liver and kidney of diabetic rats. This enzyme is key in the gluconeogenic pathway. Cinnamaldehyde also increased the activity of the glycolytic enzyme pyruvate kinase in the liver tissue of diabetic rats. It should be noted that the increased activity of glucose-6-phosphatase and fructose-1,6-bisphosphatase is associated with a gluconeogenic state. In fructose-fed-rats, the administration of *C. zeylanicum* bark extract reduced the activity of these enzymes. In 3T3-L1 adipocytes, proanthocyanidin cinnammtannin B1 (from *C. zeylanicum* bark extract) activated the phosphorylation of insulin receptors through the activation of the PI3K cascade.

4. Concept of Metabolic Reversal

- **What is metabolic reversal?**

Metabolic reversal of Type 2 Diabetes Mellitus (T2DM) refers to the restoration of normal glucose metabolism and insulin sensitivity, often leading to the discontinuation of diabetes medication. This concept challenges the traditional view of T2DM as an inevitably progressive and irreversible condition. The reversal is characterized by achieving glycated hemoglobin (HbA1c) levels below the diagnostic threshold for diabetes (typically <6.5% or <48 mmol/mol) for at least one year without glucose-lowering medication. This state is often termed "remission" and is gaining significant interest in both public and professional spheres.

The underlying mechanisms of metabolic reversal primarily involve reducing insulin resistance, improving pancreatic beta-cell function, and decreasing ectopic fat deposition in vital organs such as the liver and pancreas.



Key Factors for Metabolic Reversal Include:

1. **Reduction of Ectopic Fat:** Substantial weight loss leads to the removal of excess fat from the liver and pancreas. This process normalizes hepatic

responsiveness to insulin and alleviates metabolic stress on beta-cells, allowing them to recover function. Studies have shown that a negative calorie balance can decrease liver fat within days.

2. **Improvement in Insulin Sensitivity:** Weight loss, particularly reductions in visceral and ectopic fat, directly improves insulin sensitivity in peripheral tissues and the liver. Exercise also plays a crucial role by activating insulin-independent glucose uptake and increasing muscle insulin sensitivity. This enhanced sensitivity means the body's cells respond more effectively to insulin's signal, facilitating glucose uptake from the bloodstream.
3. **Restoration of Beta-Cell Function:** The pancreatic beta-cells, initially struggling due to fat-induced metabolic stress, can recover their ability to produce and secrete insulin once the burden of ectopic fat is removed. This recovery is more likely in individuals with a shorter duration of diabetes and higher C-peptide levels, indicating significant residual beta-cell capacity. The concept of "twin cycles" suggests that insulin resistance and impaired insulin secretion form a vicious cycle that can be reversed by reducing fat in the liver and pancreas.
4. **Hormonal and Gut Microbiota Changes:** Metabolic surgery, in particular, induces a rapid improvement in glycemic control, often before significant weight loss occurs. This is attributed to changes in gut hormones, such as Glucagon-Like Peptide-1 (GLP-1), which improve insulin sensitivity and satiety. Alterations in the gut microbiota also contribute to these metabolic improvements. Traditional Chinese medicine formulas, such as PuRenDan, have been shown to alleviate T2DM symptoms by modulating gut microbiota and its metabolites.

5. The Clinical Standard: Protocol Architecture

5.1 Patient Stratification & Baseline Profiling

- **Glycemic markers (HbA1c)**

Glycemic markers are fundamental for assessing glucose control and identifying individuals at risk for or with diabetes. Hemoglobin A1c (HbA1c) and fasting glucose (FG) are two primary measures.

HbA1c reflects the average blood glucose levels over the preceding 2-3 months due to the non-enzymatic glycation of hemoglobin within red blood cells, which have a lifespan of approximately 90-120 days. Higher HbA1c values indicate poorer long-term glucose control. A baseline HbA1c is a crucial component of initial assessments, particularly in cases like pregestational diabetes, to correlate with the risk of congenital malformations and monitor long-term glycemic management. The target HbA1c level is often individualized based on patient characteristics and clinical guidelines. While widely used, the reliability of HbA1c can be affected by conditions altering red blood cell turnover, such as anemia or certain ethnic variations, necessitating careful interpretation.

- **Insulin resistance indicators**

Insulin resistance (IR) is a multifactorial metabolic disorder underlying conditions like cardiometabolic syndrome, cardiovascular diseases, and obesity. Identifying IR is crucial for early intervention and prevention strategies.

HOMA-IR

The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is a commonly used method to estimate insulin resistance based on fasting glucose and insulin levels. It is considered a more sensitive indicator for detecting diabetes risk than fasting glucose or HbA1c alone. Studies show HOMA-IR is associated with glycated hemoglobin values independently of glycemic status.

Triglyceride/Glucose (TyG) Index

The Triglyceride/Glucose (TyG) index is another straightforward and cost-effective surrogate marker for insulin resistance, gaining recognition for its operability in clinical settings. This index has shown associations with increased risk of hyperuricemia and stroke incidence, highlighting its utility in assessing broader cardiometabolic risk.

- **Lipid and inflammatory biomarkers**

Lipid and inflammatory biomarkers are crucial for evaluating cardiovascular and systemic inflammation risks, often co-occurring with metabolic disorders.

Lipid Biomarkers

Dysregulated lipid profiles, including levels of triglycerides, high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol, are closely linked to insulin resistance and cardiometabolic diseases. The triglyceride-to-HDL ratio is a viable surrogate biomarker for insulin resistance, offering a cost-effective and straightforward alternative to more complex measures. Plasma lipidomics profiling, coupled with machine learning methods, is increasingly used to identify specific lipid characteristics associated with premetabolic syndrome and metabolic syndrome, providing potential biomarkers for early detection.

Inflammatory Biomarkers

Chronic inflammation significantly influences cancer progression and patient behavior. Inflammatory biomarkers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are important in assessing systemic inflammation. In the context of critical illness, biomarkers reflecting different pathways involved in the inflammatory response can improve the prediction of mortality risk, particularly in sepsis. For patients with diabetes and COVID-19, inflammatory markers have been shown to parallel illness severity, underscoring their relevance in acute disease management. Resveratrol, for example, has been shown to inhibit tumor progression by down-regulating NLRP3, an important inflammatory mediator, in renal cell carcinoma.

- **Lifestyle & dietary patterns**

Lifestyle and dietary patterns are profoundly influential on metabolic health, disease progression, and overall well-being.

Lifestyle Patterns

Modern lifestyles, characterized by sedentary behavior, reduced physical activity, unhealthy diets, and increased stress, contribute significantly to chronic diseases. Lifestyle patterns have been shown to influence glycemic control and other metabolic parameters in patients with type 2 diabetes. For instance, optimizing lifestyle profiles is crucial for preventing non-alcoholic fatty liver disease (NAFLD) and enhancing survival in affected individuals. Identifying and characterizing these patterns through methods like principal component analysis can help in tailoring interventions.

Dietary Patterns

Unhealthy diets are linked to obesity-related insulin resistance, inflammation, and oxidative stress, which are risk factors for several cancers. The Mediterranean diet and vegetarian diets are examples of dietary patterns extensively studied for their cardiovascular health benefits. In adult survivors of childhood cancer, specific dietary patterns are identified and associated with sociodemographic and lifestyle factors, underscoring the importance of dietary assessment in long-term health outcomes. Personalized nutritional interventions and computational models, such as the Mixed Meal Model, can characterize metabolic health and assess the impact of dietary changes on metabolic resilience.

6. The iThrive Way:

The iThrive approach to addressing Type 2 diabetes, as observed across documented cases, is implemented through a structured three-month protocol that emphasizes dietary modification, lifestyle restructuring, and supportive nutritional supplementation. The approach addresses diabetes alongside co-existing symptoms rather than treating blood glucose levels as an isolated clinical parameter.

Dietary Elimination Phase

At the start of the protocol, dietary modification forms the primary intervention. In the documented cases, specific food groups were removed from daily intake. These included gluten, dairy, refined sugar, seed oils, corn, soy products, processed foods, and excess salt. This phase was introduced early in the program and was consistent across cases. Dietary elimination was accompanied by guidance on food selection and the importance of avoiding processed and packaged foods during the intervention period.

Structured Meal Patterns and Food Consistency

Following the initial elimination phase, structured eating patterns were introduced. Meals were organized into a defined daily routine with emphasis on regular meal timing. Home-cooked meals were encouraged, and consistency in food choices was reinforced throughout the three-month protocol. Participants were guided to maintain these dietary practices even during periods of travel or changes in routine.

Progressive Dietary Refinement

As the protocol progressed, dietary intake was further refined. Protein-rich food options were increased, and variety within the permitted food framework was encouraged. In some cases, herbal teas, spices, and simple home-based dietary preparations were incorporated as part of ongoing dietary support. Education on food hygiene practices, including the proper cleaning of fruits and vegetables, was also included during this phase.

Lifestyle Integration Alongside Dietary Changes

Dietary interventions were supported by concurrent lifestyle adjustments. Documented cases included the establishment of regular sleep routines, increased sunlight exposure, incorporation of breathwork practices, and guidance on reducing exposure to household and environmental toxins. Physical activity was continued or modified based on individual capacity and routine. These lifestyle elements were implemented alongside dietary changes as part of the overall protocol.

Supportive Nutritional Supplementation

The inclusion of nutritional supplements provided supportive coverage during the dietary transition period. Supplementation was used consistently alongside dietary and lifestyle modifications and supported nutritional adequacy during the elimination and refinement phases. This approach helped maintain continuity of the protocol while dietary habits were being adjusted.

Monitoring and Outcome Evaluation

Clinical monitoring was conducted through symptom tracking and follow-up blood assessments. Blood glucose parameters were reviewed before and after the intervention, and medication requirements were reassessed over time. In documented outcomes, improvement in blood glucose values was observed, and in one case, diabetes medication was discontinued following completion of the protocol.

Conclusion of this study

The traditional approach to Type 2 diabetes management has been shaped by the assumption that the disease is irreversible, necessitating lifelong pharmacological intervention. While medications play an important role in controlling blood glucose and preventing acute complications, they often leave the core metabolic dysfunction

untouched. As a result, many individuals experience gradual disease progression despite intensifying therapy. The evidence discussed in this review challenges this model and supports a more nuanced understanding of T2DM as a consequence of prolonged metabolic overload rather than permanent pancreatic failure.

By addressing the upstream drivers of insulin resistance, such as chronic caloric excess, poor metabolic flexibility, inflammation, and mitochondrial stress, metabolic function can be meaningfully restored. Reductions in liver and pancreatic fat, improvements in insulin signaling, and partial recovery of β-cell function demonstrate that the body retains a remarkable capacity for repair when adverse metabolic conditions are removed. Importantly, these changes extend beyond glucose control, contributing to broader improvements in lipid metabolism, energy regulation, and systemic inflammation.

Reframing Type 2 diabetes as a reversible metabolic condition has important implications for both clinical practice and public health. It emphasizes early intervention, individualized metabolic assessment, and strategies that prioritize long-term physiological resilience over short-term glycemic suppression. As research continues to evolve, a root-cause focused approach to metabolic health offers a more sustainable, empowering, and biologically aligned path forward in the management of Type 2 diabetes.

Referencing

6. Glycemic Targets: *Standards of Medical Care in Diabetes—2022*. (2022). *Diabetes Care*, *45*(Supplement_1), S83–S96. https://doi.org/10.2337/dc22-S006

Abdullah, M., Abdo, B., AlShoaibi, I., Alzanen, K., Alhakamy, M., & Al-Namer, M. (2025). Prevalence and determinants of hypomagnesemia in type 2 diabetes mellitus: A retrospective cross-sectional study from a resource-limited setting. *Medicine*, *104*(32), e43851. https://doi.org/10.1097/MD.0000000000043851

Adithya, B. S., Nayeem, M., Sagar, N. A., & Kumar, S. (2025a). Therapeutic Potentials of Jamun (*Syzygium cumini*) and Its Integration Into Modern Food Technologies: A Review. *International Journal of Food Science*, *2025*(1). https://doi.org/10.1155/ijfo/8197889

Adithya, B. S., Nayeem, M., Sagar, N. A., & Kumar, S. (2025b). Therapeutic Potentials of Jamun (*Syzygium cumini*) and Its Integration Into Modern Food Technologies: A Review. *International Journal of Food Science*, *2025*(1). https://doi.org/10.1155/ijfo/8197889

Ahmed, B., Sultana, R., & Greene, M. W. (2021). Adipose tissue and insulin resistance in obese. *Biomedicine & Pharmacotherapy*, *137*, 111315. https://doi.org/10.1016/j.biopha.2021.111315

Ahmed, Yasir, Mohamed Abuelass, F. K., Hamd Abdelwahab, S. B., Mukhtar, M., Ahmed, Yousri, Elfahal, M., & Mohmed Elhussein, N. S. (2025). Determinants of Poor Glycemic Control Among Type 2 Diabetes Patients: A Systematic Review. *Cureus*. https://doi.org/10.7759/cureus.82464

Akalestou, E., Miras, A. D., Rutter, G. A., & le Roux, C. W. (2022). Mechanisms of Weight Loss After Obesity Surgery. *Endocrine Reviews*, *43*(1), 19–34. https://doi.org/10.1210/endrev/bnab022

Al-Attas, O. S., Al-Daghri, N. M., Al-Rubeaan, K., da Silva, N. F., Sabico, S. L., Kumar, S., McTernan, P. G., & Harte, A. L. (2009). Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. *Cardiovascular Diabetology*, *8*(1), 20. https://doi.org/10.1186/1475-2840-8-20

Al-Hassani, I., Khan, N. A., Elmenyar, E., Al-Hassani, A., Rizoli, S., Al-Thani, H., & El-Menyar, A. (2024). The Interaction and Implication of Stress-Induced Hyperglycemia and Cytokine Release Following Traumatic Injury: A Structured Scoping Review. *Diagnostics*, *14*(23), 2649. https://doi.org/10.3390/diagnostics14232649

Amaral, L. M. P. F., Moniz, T., Silva, A. M. N., & Rangel, M. (2023). Vanadium Compounds with Antidiabetic Potential. *International Journal of Molecular Sciences*, *24*(21), 15675. https://doi.org/10.3390/ijms242115675

Anand, P., Murali, K. Y., Tandon, V., Murthy, P. S., & Chandra, R. (2010). Insulinotropic effect of cinnamaldehyde on transcriptional regulation of pyruvate kinase, phosphoenolpyruvate carboxykinase, and GLUT4 translocation in experimental diabetic rats. *Chemico-Biological Interactions*, *186*(1), 72–81. https://doi.org/10.1016/j.cbi.2010.03.044

Anjana, R. M., Sudha, V., Abirami, K., Gayathri, R., Manasa, V. S., & Deepa, M. (2025). Dietary profiles and associated metabolic risk factors in India from the ICMR–INDIAB survey-21. *Nature Medicine*, *31*(11), 3813–3824. https://doi.org/10.1038/s41591-025-03949-4

Antoun, G., McMurray, F., Thrush, A. B., & Patten, D. A. (2015). Impaired mitochondrial oxidative phosphorylation and supercomplex assembly in rectus abdominis muscle of diabetic obese individuals. *Diabetologia*, *58*(12), 2861–2866. https://doi.org/10.1007/s00125-015-3772-8

Argano, C., Orlando, V., Maggio, D., Pollicino, C., & Torres, A. (2025). Pathophysiological Role and Therapeutic Potential of Vitamin C in Metabolic Syndrome and Type 2 Diabetes Mellitus. *Metabolites*, *15*(12), 773. https://doi.org/10.3390/metabo15120773

Asanaliyar, M., & Nadig, P. (2020). Syzygium cumini (jamun) therapeutic potential: a comprehensive review on phytochemical constituents and emphasis on its pharmacological actions related to diabetic intervention. *International Journal of Basic & Clinical Pharmacology*, *9*(2), 363. https://doi.org/10.18203/2319-2003.ijbcp20200192

Asbaghi, O., Fatemeh, N., Mahnaz, R. K., Ehsan, G., & Elham, E. (2020). Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Pharmacological Research*, *161*, 105098. https://doi.org/10.1016/j.phrs.2020.105098

Asbaghi, O., Moradi, S., Kashkooli, S., Zobeiri, M., & Nezamoleslami, S. (2022). The effects of oral magnesium supplementation on glycaemic control in patients with type 2 diabetes: a systematic review and dose–response meta-analysis of controlled clinical trials. *British Journal of Nutrition*, *128*(12), 2363–2372. https://doi.org/10.1017/S0007114521005201

Ashor, A. W., Werner, A. D., Lara, J., Willis, N. D., Mathers, J. C., & Siervo, M. (2017). Effects of vitamin C supplementation on glycaemic control: a systematic review and meta-analysis of randomised controlled trials. *European Journal of Clinical Nutrition*, *71*(12), 1371–1380. https://doi.org/10.1038/ejcn.2017.24

Balan, A. I., Halațiu, V. B., & Scridon, A. (2024). Oxidative Stress, Inflammation, and Mitochondrial Dysfunction: A Link between Obesity and Atrial Fibrillation. *Antioxidants*, *13*(1), 117. https://doi.org/10.3390/antiox13010117

Banerjee, A., Somasundaram, I., Das, D., Jain Manoj, S., Banu, H., Mitta Suresh, P., & Paul, S. (2023). Functional Foods: A Promising Strategy for Restoring Gut Microbiota Diversity Impacted by SARS-CoV-2 Variants. *Nutrients*, *15*(11), 2631. https://doi.org/10.3390/nu15112631

Belančić, A., Sener, Y. Z., Vučković, M., Blais, J. E., Fajkić, A., Sher, E., Radić, M., & Radić, J. (2025). Blood pressure effects of SGLT2 inhibitors and GLP-1 receptor agonists: Mechanisms, trial evidence and Real-world data. *British Journal of Clinical Pharmacology*. https://doi.org/10.1002/bcp.70378

Berbudi, A., Khairani, S., & Tjahjadi, A. (2025). Interplay Between Insulin Resistance and Immune Dysregulation in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions. *ImmunoTargets and Therapy*, *Volume 14*, 359–382. https://doi.org/10.2147/ITT.S499605

Boucher, J., Kleinridders, A., & Kahn, C. R. (2014). Insulin Receptor Signaling in Normal and Insulin-Resistant States. *Cold Spring Harbor Perspectives in Biology*, *6*(1), a009191–a009191. https://doi.org/10.1101/cshperspect.a009191

Burhans, M. S., Hagman, D. K., Kuzma, J. N., Schmidt, K. A., & Kratz, M. (2018). Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus. In *Comprehensive Physiology* (pp. 1–58). Wiley. https://doi.org/10.1002/cphy.c170040

Cardelo, M. P., Alcala-Diaz, J. F., Gutierrez-Mariscal, F. M., Lopez-Moreno, J., Villasanta-Gonzalez, A., Arenas-de Larriva, A. P., & Cruz-Ares, S. de la. (2022). Diabetes Remission Is Modulated by Branched Chain Amino Acids According to the Diet Consumed: From the CORDIOPREV Study. *Molecular Nutrition & Food Research*, *66*(4). https://doi.org/10.1002/mnfr.202100652

Cefalu, W. T., & Hu, F. B. (2004). Role of Chromium in Human Health and in Diabetes. *Diabetes Care*, *27*(11), 2741–2751. https://doi.org/10.2337/diacare.27.11.2741

Cerf, M. E. (2013). Beta Cell Dysfunction and Insulin Resistance. *Frontiers in Endocrinology*, *4*. https://doi.org/10.3389/fendo.2013.00037

Ciesielska, A., Matyjek, M., & Kwiatkowska, K. (2021). TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. *Cellular and Molecular Life Sciences*, *78*(4), 1233–1261. https://doi.org/10.1007/s00018-020-03656-y

Clemente-Suárez, V. J., Martín-Rodríguez, A., Beltrán-Velasco, A. I., Rubio-Zarapuz, A., Martínez-Guardado, I., Valcárcel-Martín, R., & Tornero-Aguilera, J. F. (2025). Functional and Therapeutic Roles of Plant-Derived Antioxidants in Type 2 Diabetes Mellitus: Mechanisms, Challenges, and Considerations for Special Populations. *Antioxidants*, *14*(6), 725. https://doi.org/10.3390/antiox14060725

Corbin, L. J., Hughes, D. A., Bull, C. J., Vincent, E. E., Smith, M. L., & McConnachie, A. (2024). The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT). *Diabetologia*, *67*(1), 74–87. https://doi.org/10.1007/s00125-023-06019-x

Cortez-Navarrete, M., Pérez-Rubio, K. G., & Escobedo-Gutiérrez, M. de J. (2023). Role of Fenugreek, Cinnamon, Curcuma longa, Berberine and Momordica charantia in Type 2 Diabetes Mellitus Treatment: A Review. *Pharmaceuticals*, *16*(4), 515. https://doi.org/10.3390/ph16040515

Costello, R. B., Dwyer, J. T., & Bailey, R. L. (2016). Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. *Nutrition Reviews*, *74*(7), 455–468. https://doi.org/10.1093/nutrit/nuw011

Das, S., Mukhuty, A., Mullen, G. P., & Rudolph, M. C. (2024). Adipocyte Mitochondria: Deciphering Energetic Functions across Fat Depots in Obesity and Type 2 Diabetes. *International Journal of Molecular Sciences*, *25*(12), 6681. https://doi.org/10.3390/ijms25126681

Davies, M. J., Aroda, V. R., & Collins, B. S. (2022). Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, *45*(11), 2753–2786. https://doi.org/10.2337/dci22-0034

DeFronzo, R. A., & Tripathy, D. (2009). Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes. *Diabetes Care*, *32*(suppl_2), S157–S163. https://doi.org/10.2337/dc09-S302

del Prato, S., Penno, G., & Miccoli, R. (2009). Changing the Treatment Paradigm for Type 2 Diabetes. *Diabetes Care*, *32*(suppl_2), S217–S222. https://doi.org/10.2337/dc09-S314

DiNicolantonio, J. J., & O'Keefe, J. H. (2018). Omega-6 vegetable oils as a driver of coronary heart disease: the oxidized linoleic acid hypothesis. *Open Heart*, *5*(2), e000898. https://doi.org/10.1136/openhrt-2018-000898

Do, M. T. H., & Yau, K.-W. (2010). Intrinsically Photosensitive Retinal Ganglion Cells. *Physiological Reviews*, *90*(4), 1547–1581. https://doi.org/10.1152/physrev.00013.2010

Doucet, J., Gourdy, P., Meyer, L., Benabdelmoumene, N., & Bourdel-Marchasson, I. (2023). Management of Glucose-Lowering Therapy in Older Adults with Type 2 Diabetes: Challenges and Opportunities. *Clinical Interventions in Aging*, *Volume 18*, 1687–1703. https://doi.org/10.2147/CIA.S423122

Elkanawati, R., Sumiwi, S., & Levita, J. (2024). Impact of Lipids on Insulin Resistance: Insights from Human and Animal Studies. *Drug Design, Development and Therapy*, *Volume 18*, 3337–3360. https://doi.org/10.2147/DDDT.S468147

Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Woodgett, J. R., & Mills, G. B. (2000). Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. *Proceedings of the National Academy of Sciences*, *97*(22), 11960–11965. https://doi.org/10.1073/pnas.220413597

Favaretto, F., Milan, G., Collin, G. B., Marshall, J. D., & Naggert, J. K. (2014). GLUT4 Defects in Adipose Tissue Are Early Signs of Metabolic Alterations in Alms1GT/GT, a Mouse Model for Obesity and Insulin Resistance. *PLoS ONE*, *9*(10), e109540. https://doi.org/10.1371/journal.pone.0109540

Gál, R., Halmosi, R., Gallyas, F., Tschida, M., Mutirangura, P., Tóth, K., Alexy, T., & Czopf, L. (2023). Resveratrol and beyond: The Effect of Natural Polyphenols on the Cardiovascular System: A Narrative Review. *Biomedicines*, *11*(11), 2888. https://doi.org/10.3390/biomedicines11112888

Gale, J. E., Cox, H. I., Qian, J., Block, G. D., Colwell, C. S., & Matveyenko, A. v. (2011). Disruption of Circadian Rhythms Accelerates Development of Diabetes through Pancreatic Beta-Cell Loss and Dysfunction. *Journal of Biological Rhythms*, *26*(5), 423–433. https://doi.org/10.1177/0748730411416341

Galindo, R. J., Trujillo, J. M., Low Wang, C. C., & McCoy, R. G. (2023a). Advances in the management of type 2 diabetes in adults. *BMJ Medicine*, *2*(1), e000372. https://doi.org/10.1136/bmjmed-2022-000372

Galindo, R. J., Trujillo, J. M., Low Wang, C. C., & McCoy, R. G. (2023b). Advances in the management of type 2 diabetes in adults. *BMJ Medicine*, *2*(1), e000372. https://doi.org/10.1136/bmjmed-2022-000372

García-González, V. G., Morales, A. B. O., Navarro Padrón, A. C., Chimal-Vega, B., & Sánchez-Alavez, M. (2025). Advances in the development of protein tyrosine phosphatase 1B inhibitor, evaluated by in vitro and in vivo assays. *Results in Chemistry*, *16*, 102465. https://doi.org/10.1016/j.rechem.2025.102465

Ghosh, S. S., Wang, J., Yannie, P. J., & Ghosh, S. (2020). Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development. *Journal of the Endocrine Society*, *4*(2). https://doi.org/10.1210/jendso/bvz039

Gieroba, B., Kryska, A., & Sroka-Bartnicka, A. (2025a). Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment. *Biochemistry and Biophysics Reports*, *42*, 102037. https://doi.org/10.1016/j.bbrep.2025.102037

Gieroba, B., Kryska, A., & Sroka-Bartnicka, A. (2025b). Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment. *Biochemistry and Biophysics Reports*, *42*, 102037. https://doi.org/10.1016/j.bbrep.2025.102037

Golbidi, S., Badran, M., & Laher, I. (2011). Diabetes and Alpha Lipoic Acid. *Frontiers in Pharmacology*, *2*. https://doi.org/10.3389/fphar.2011.00069

He, K.-J., Wang, H., Xu, J., Gong, G., Liu, X., & Guan, H. (2024). Global burden of type 2 diabetes mellitus from 1990 to 2021, with projections of prevalence to 2044: a systematic analysis across SDI levels for the global burden of disease study 2021. *Frontiers in Endocrinology*, *15*. https://doi.org/10.3389/fendo.2024.1501690

Hine, J., Schwell, A., & Kairys, N. (2017). An Unlikely Cause of Hypokalemia. *The Journal of Emergency Medicine*, *52*(5), e187–e191. https://doi.org/10.1016/j.jemermed.2016.12.011

Hodish, I. (2020). For debate; pharmacological priorities in advanced type 2 diabetes. *Journal of Diabetes and Its Complications*, *34*(5), 107510. https://doi.org/10.1016/j.jdiacomp.2019.107510

Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., & Klupa, T. (2021). The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, *44*(11), 2589–2625. https://doi.org/10.2337/dci21-0043

Hong, S. H., Lee, D.-B., Yoon, D.-W., & Kim, J. (2024). Melatonin Improves Glucose Homeostasis and Insulin Sensitivity by Mitigating Inflammation and Activating AMPK Signaling in a Mouse Model of Sleep Fragmentation. *Cells*, *13*(6), 470. https://doi.org/10.3390/cells13060470

Hongzhou Liu, Nan Li, & Mengmeng Jin. (2020). Magnesium supplementation enhances insulin sensitivity and decreases insulin resistance in diabetic rats. *Iranian Journal of Basic Medical Sciences.* .

Horáková, D., Štěpánek, Ladislav, Janout, V., Janoutová, J., Pastucha, D., Kollárová, H., Petráková, A., Štěpánek, Lubomír, Husár, R., & Martiník, K. (2019). Optimal Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Cut-Offs: A Cross-Sectional Study in the Czech Population. *Medicina*, *55*(5), 158. https://doi.org/10.3390/medicina55050158

Huang, H., Chen, G., Dong, Y., Zhu, Y., & Chen, H. (2018). Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: Results from a pooled analysis. *Molecular Nutrition & Food Research*, *62*(1). https://doi.org/10.1002/mnfr.201700438

Huang, T., Lu, K.-N., Pai, Y.-P., Chin Hsu, & Huang, C. (2013). Role of GLP-1 in the Hypoglycemic Effects of Wild Bitter Gourd. *Evidence-Based Complementary and Alternative Medicine*, *2013*, 1–13. https://doi.org/10.1155/2013/625892

Hutch, C. R., & Sandoval, D. (2017). The Role of GLP-1 in the Metabolic Success of Bariatric Surgery. *Endocrinology*, *158*(12), 4139–4151. https://doi.org/10.1210/en.2017-00564

Janssen, J. A. M. J. L. (2024). The Causal Role of Ectopic Fat Deposition in the Pathogenesis of Metabolic Syndrome. *International Journal of Molecular Sciences*, *25*(24), 13238. https://doi.org/10.3390/ijms252413238

Janssen, J. A. M. J. L. (2025). The Pivotal Role of the Western Diet, Hyperinsulinemia, Ectopic Fat, and Diacylglycerol-Mediated Insulin Resistance in Type 2 Diabetes. *International Journal of Molecular Sciences*, *26*(18), 9191. https://doi.org/10.3390/ijms26189191

Jia, S., Shen, M., Zhang, F., & Xie, J. (2017). Recent Advances in Momordica charantia: Functional Components and Biological Activities. *International Journal of Molecular Sciences*, *18*(12), 2555. https://doi.org/10.3390/ijms18122555

Jiang, G., Luk, A. O., Tam, C. H. T., Lau, E. S., & Ozaki, R. (2020). Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank. *PLOS Medicine*, *17*(7), e1003209. https://doi.org/10.1371/journal.pmed.1003209

Jin, Y., Shi, Y., Zou, Y., Miao, C., Sun, B., & Li, C. (2014). Fenugreek Prevents the Development of STZ‐Induced Diabetic Nephropathy in a Rat Model of Diabetes. *Evidence-Based Complementary and Alternative Medicine*, *2014*(1). https://doi.org/10.1155/2014/259368

Juraschek, S. P., Steffes, M. W., & Selvin, E. (2012). Associations of Alternative Markers of Glycemia with Hemoglobin A1c and Fasting Glucose. *Clinical Chemistry*, *58*(12), 1648–1655. https://doi.org/10.1373/clinchem.2012.188367

Kaiafa, G., Veneti, S., Polychronopoulos, G., Pilalas, D., Daios, S., Kanellos, I., Didangelos, T., Pagoni, S., & Savopoulos, C. (2021). Is HbA1c an ideal biomarker of well-controlled diabetes? *Postgraduate Medical Journal*, *97*(1148), 380–383. https://doi.org/10.1136/postgradmedj-2020-138756

Kane, A. E., & Sinclair, D. A. (2018). Sirtuins and NAD $^{+}$ in the Development and Treatment of Metabolic and Cardiovascular Diseases. *Circulation Research*, *123*(7), 868–885. https://doi.org/10.1161/CIRCRESAHA.118.312498

Kannan, P., Raghunathan, M., Mohan, T., Palanivelu, S., & Periandavan, K. (2022). Gymnemic Acid Ameliorates Pancreatic β-Cell Dysfunction by Modulating Pdx1 Expression: A Possible Strategy for β-Cell Regeneration. *Tissue Engineering and Regenerative Medicine*, *19*(3), 603–616. https://doi.org/10.1007/s13770-022-00435-7

Khalid, M., Petroianu, G., & Adem, A. (2022). Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. *Biomolecules*, *12*(4), 542. https://doi.org/10.3390/biom12040542

Kibirige, D., Sekitoleko, I., Lumu, W., & Nyirenda, M. J. (2023). Type 2 diabetes progression in an adult Ugandan population with new-onset diabetes: an observational prospective study. *BMC Primary Care*, *24*(1), 214. https://doi.org/10.1186/s12875-023-02169-4

Kim, J., Wei, Y., & Sowers, J. R. (2008). Role of Mitochondrial Dysfunction in Insulin Resistance. *Circulation Research*, *102*(4), 401–414. https://doi.org/10.1161/CIRCRESAHA.107.165472

Kosmas, C. E., Rodriguez Polanco, S., Bousvarou, M. D., Papakonstantinou, E. J., Peña Genao, E., Guzman, E., & Kostara, C. E. (2023). The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. *Diagnostics*, *13*(5), 929. https://doi.org/10.3390/diagnostics13050929

Le, T. K. C., Dao, X. D., Nguyen, D. V., Luu, D. H., & Bui, T. M. H. (2023). Insulin signaling and its application. *Frontiers in Endocrinology*, *14*. https://doi.org/10.3389/fendo.2023.1226655

Le, T. K. C., Dao, X. D., Nguyen, D. V., Luu, D. H., Bui, T. M. H., Le, T. H., Nguyen, H. T., Le, T. N., Hosaka, T., & Nguyen, T. T. T. (2023). Insulin signaling and its application. *Frontiers in Endocrinology*, *14*. https://doi.org/10.3389/fendo.2023.1226655

Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., & Al-Mrabeh, A. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *The Lancet*, *391*(10120), 541–551. https://doi.org/10.1016/S0140-6736(17)33102-1

Lee, S.-H., Park, S.-Y., & Choi, C. S. (2022). Insulin Resistance: From Mechanisms to Therapeutic Strategies. *Diabetes & Metabolism Journal*, *46*(1), 15–37. https://doi.org/10.4093/dmj.2021.0280

Leiu, K., Poppitt, S., Miles-Chan, J., & Sequeira, I. (2022). Fatty Pancreas and Cardiometabolic Risk: Response of Ectopic Fat to Lifestyle and Surgical Interventions. *Nutrients*, *14*(22), 4873. https://doi.org/10.3390/nu14224873

Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022). Trends in insulin resistance: insights into mechanisms and therapeutic strategy. *Signal Transduction and Targeted Therapy*, *7*(1), 216. https://doi.org/10.1038/s41392-022-01073-0

Li, X., Chen, W., Jia, Z., Xiao, Y., Shi, A., & Ma, X. (2025). Mitochondrial Dysfunction as a Pathogenesis and Therapeutic Strategy for Metabolic-Dysfunction-Associated Steatotic Liver Disease. *International Journal of Molecular Sciences*, *26*(9), 4256. https://doi.org/10.3390/ijms26094256

Liang, Y., Liang, J., Jiang, W., Wang, W., Yang, X., & Liu, Y. (2024). Stronger association between morning serum cortisol level and diurnal time in range in type 2 diabetes? *Diabetology & Metabolic Syndrome*, *16*(1), 290. https://doi.org/10.1186/s13098-024-01515-5

Lipke, K., Kubis-Kubiak, A., & Piwowar, A. (2022). Molecular Mechanism of Lipotoxicity as an Interesting Aspect in the Development of Pathological States—Current View of Knowledge. *Cells*, *11*(5), 844. https://doi.org/10.3390/cells11050844

Lisco, G., Giagulli, V. A., de Pergola, G., Guastamacchia, E., Jirillo, E., Vitale, E., & Triggiani, V. (2024). Chronic Stress as a Risk Factor for Type 2 Diabetes: Endocrine, Metabolic, and Immune Implications. *Endocrine, Metabolic & Immune Disorders - Drug Targets*, *24*(3), 321–332. https://doi.org/10.2174/1871530323666230803095118

Liu, D., Zhao, L., Wang, Y., Wang, L., Wu, D., & Liu, Y. (2025). Berberine: A Rising Star in the Management of Type 2 Diabetes—Novel Insights into Its Anti-Inflammatory, Metabolic, and Epigenetic Mechanisms. *Pharmaceuticals*, *18*(12), 1890. https://doi.org/10.3390/ph18121890

Liu, Y., Gang, X., Liu, X., Jiang, W., Yang, Y., & Wang, G. (2025). Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives. *Frontiers in Endocrinology*, *16*. https://doi.org/10.3389/fendo.2025.1687601

Maddaloni, E., Bolli, G. B., Frier, B. M., Little, R. R., Leslie, R. D., Pozzilli, P., & Buzzetti, R. (2022). C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective. *Diabetes, Obesity and Metabolism*, *24*(10), 1912–1926. https://doi.org/10.1111/dom.14785

Mayyas, A., Al-Samydai, A., Oraibi, A. I., Debbabi, N., & Hassan, S. S. (2025). Deciphering the Anti-Diabetic Potential of *Gymnema Sylvestre* Using Integrated Computer-Aided Drug Design and Network Pharmacology. *Journal of Cellular and Molecular Medicine*, *29*(1). https://doi.org/10.1111/jcmm.70349

Merz, K. E., & Thurmond, D. C. (2020). Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. In *Comprehensive Physiology* (pp. 785–809). Wiley. https://doi.org/10.1002/cphy.c190029

Mohammad, S., & Thiemermann, C. (2021). Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. *Frontiers in Immunology*, *11*. https://doi.org/10.3389/fimmu.2020.594150

Muzaffar, H., Qamar, I., Bashir, M., Jabeen, F., Irfan, S., & Anwar, H. (2023). Gymnema Sylvestre Supplementation Restores Normoglycemia, Corrects Dyslipidemia, and

Transcriptionally Modulates Pancreatic and Hepatic Gene Expression in Alloxan-Induced Hyperglycemic Rats. *Metabolites*, *13*(4), 516. https://doi.org/10.3390/metabo13040516

Park, S.-J., Ahmad, F., Um, J.-H., Brown, A. L., Xu, X., Kang, H., Ke, H., Feng, X., Ryall, J., Philp, A., Schenk, S., Kim, M. K., Sartorelli, V., & Chung, J. H. (2017). Specific Sirt1 Activator-mediated Improvement in Glucose Homeostasis Requires Sirt1-Independent Activation of AMPK. *EBioMedicine*, *18*, 128–138. https://doi.org/10.1016/j.ebiom.2017.03.019

Patel, S., Huang, M., & Miliara, S. (2025). Understanding Treatment Adherence in Chronic Diseases: Challenges, Consequences, and Strategies for Improvement. *Journal of Clinical Medicine*, *14*(17), 6034. https://doi.org/10.3390/jcm14176034

Pussinen, P. J., Havulinna, A. S., Lehto, M., Sundvall, J., & Salomaa, V. (2011). Endotoxemia Is Associated With an Increased Risk of Incident Diabetes. *Diabetes Care*, *34*(2), 392–397. https://doi.org/10.2337/dc10-1676

Qin, L., Fan, B., Zhou, Y., Zheng, J., Diao, R., Wang, F., & Liu, J. (2025). Targeted gut microbiome therapy: Applications and prospects of probiotics, fecal microbiota transplantation and natural products in the management of type 2 diabetes. *Pharmacological Research*, *213*, 107625. https://doi.org/10.1016/j.phrs.2025.107625

Ramírez-Camacho, I., García-Niño, W. R., Flores-García, M., Pedraza-Chaverri, J., & Zazueta, C. (2020). Alteration of mitochondrial supercomplexes assembly in metabolic diseases. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, *1866*(12), 165935. https://doi.org/10.1016/j.bbadis.2020.165935

Religioni, U., Barrios-Rodríguez, R., Requena, P., Borowska, M., & Ostrowski, J. (2025). Enhancing Therapy Adherence: Impact on Clinical Outcomes, Healthcare Costs, and Patient Quality of Life. *Medicina*, *61*(1), 153. https://doi.org/10.3390/medicina61010153

Richter, E., Geetha, T., Burnett, D., Broderick, T. L., & Babu, J. R. (2023). The Effects of Momordica charantia on Type 2 Diabetes Mellitus and Alzheimer's Disease. *International Journal of Molecular Sciences*, *24*(5), 4643. https://doi.org/10.3390/ijms24054643

Rizo‐Roca, D., Henderson, J. D., & Zierath, J. R. (2025). Metabolomics in cardiometabolic diseases: Key biomarkers and therapeutic implications for insulin resistance and diabetes. *Journal of Internal Medicine*, *297*(6), 584–607. https://doi.org/10.1111/joim.20090

Rizvi, M. K., Rabail, R., Munir, S., Inam-Ur-Raheem, M., & Qayyum, M. M. N. (2022). Astounding Health Benefits of Jamun (Syzygium cumini) toward Metabolic Syndrome. *Molecules*, *27*(21), 7184. https://doi.org/10.3390/molecules27217184

Rodriguez-Gutierrez, R., & McCoy, R. G. (2019). Measuring What Matters in Diabetes. *JAMA*, *321*(19), 1865. https://doi.org/10.1001/jama.2019.4310

Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & Gąsecka, A. (2023). SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain. *Journal of Cardiovascular Development and Disease*, *10*(8), 322. https://doi.org/10.3390/jcdd10080322

Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., & Karuranga, S. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Research and Clinical Practice*, *157*, 107843. https://doi.org/10.1016/j.diabres.2019.107843

Salomon, I., Sam, S., Rehman, Y. U., & Hope, I. M. (2025). Artificial light exposure at night: A hidden risk factor for type 2 diabetes. *Sleep Medicine: X*, *10*, 100146. https://doi.org/10.1016/j.sleepx.2025.100146

Samuel, V. T., & Shulman, G. I. (2012). Mechanisms for Insulin Resistance: Common Threads and Missing Links. *Cell*, *148*(5), 852–871. https://doi.org/10.1016/j.cell.2012.02.017

Sanematsu, K., Kusakabe, Y., Shigemura, N., Hirokawa, T., Nakamura, S., Imoto, T., & Ninomiya, Y. (2014). Molecular Mechanisms for Sweet-suppressing Effect of Gymnemic Acids. *Journal of Biological Chemistry*, *289*(37), 25711–25720. https://doi.org/10.1074/jbc.M114.560409

Sarker, D. K., Ray, P., Dutta, A. K., Rouf, R., & Uddin, S. J. (2024). Antidiabetic potential of fenugreek (*Trigonella foenum‐graecum*): A magic herb for diabetes mellitus. *Food Science & Nutrition*, *12*(10), 7108–7136. https://doi.org/10.1002/fsn3.4440

SENANAYAKE, G. V. K., MARUYAMA, M., SAKONO, M., FUKUDA, N., & MORISHITA, T. (2004). The Effects of Bitter Melon (Momordica charantia) Extracts on Serum and Liver Lipid Parameters in Hamsters Fed Cholesterol-Free and Cholesterol-Enriched Diets. *Journal of Nutritional Science and Vitaminology*, *50*(4), 253–257. https://doi.org/10.3177/jnsv.50.253

Senevirathne, B. S., Jayasinghe, M. A., Pavalakumar, D., & Siriwardhana, C. G. (2022). Ceylon cinnamon: a versatile ingredient for futuristic diabetes management. *Journal of Future Foods*, *2*(2), 125–142. https://doi.org/10.1016/j.jfutfo.2022.03.010

Sergi, D., Naumovski, N., Heilbronn, L. K., Abeywardena, M., O'Callaghan, N., Lionetti, L., & Luscombe-Marsh, N. (2019). Mitochondrial (Dys)function and Insulin Resistance: From Pathophysiological Molecular Mechanisms to the Impact of Diet. *Frontiers in Physiology*, *10*. https://doi.org/10.3389/fphys.2019.00532

Shanahan, C. (2025). The energy model of insulin resistance: A unifying theory linking seed oils to metabolic disease and cancer. *Frontiers in Nutrition*, *12*. https://doi.org/10.3389/fnut.2025.1532961

Sharabi, K., Tavares, C. D. J., Rines, A. K., & Puigserver, P. (2015). Molecular pathophysiology of hepatic glucose production. *Molecular Aspects of Medicine*, *46*, 21–33. https://doi.org/10.1016/j.mam.2015.09.003

Sheng, J. A., Bales, N. J., Myers, S. A., Bautista, A. I., Roueinfar, M., Hale, T. M., & Handa, R. J. (2021). The Hypothalamic-Pituitary-Adrenal Axis: Development, Programming Actions of Hormones, and Maternal-Fetal Interactions. *Frontiers in Behavioral Neuroscience*, *14*. https://doi.org/10.3389/fnbeh.2020.601939

Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016). Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. *Biomarker Insights*, *11*, BMI.S38440. https://doi.org/10.4137/BMI.S38440

Silvia, P., Simona, Z., Ernesto, M., & Raffaella, B. (2020). "H" for Heterogeneity in the Algorithm for Type 2 Diabetes Management. *Current Diabetes Reports*, *20*(5), 14. https://doi.org/10.1007/s11892-020-01297-w

Sinclair, A. J., Heller, S. R., Pratley, R. E., Duan, R., Heine, R. J., Festa, A., & Kiljański, J. (2020). Evaluating glucose‐lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial. *Diabetes, Obesity and Metabolism*, *22*(8), 1231–1242. https://doi.org/10.1111/dom.14013

Singer, G. M., & Geohas, J. (2006). The Effect of Chromium Picolinate and Biotin Supplementation on Glycemic Control in Poorly Controlled Patients with Type 2 Diabetes Mellitus: A Placebo-Controlled, Double-Blinded, Randomized Trial. *Diabetes Technology & Therapeutics*, *8*(6), 636–643. https://doi.org/10.1089/dia.2006.8.636

Singh, C. K., Liu, X., & Ahmad, N. (2015). Resveratrol, in its natural combination in whole grape, for health promotion and disease management. *Annals of the New York Academy of Sciences*, *1348*(1), 150–160. https://doi.org/10.1111/nyas.12798

Singh, D., Nandni, & Bedi, N. (2025). Honokiol as a next-generation phytotherapeutic: Anticancer, neuroprotective, and nanomedicine perspectives. *Pharmacological Research - Modern Chinese Medicine*, *17*, 100713. https://doi.org/10.1016/j.prmcm.2025.100713

Singh, K., & Ahluwalia, P. (2012). Effect of monosodium glutamate on lipid peroxidation and certain antioxidant enzymes in cardiac tissue of alcoholic adult male mice. *Journal of Cardiovascular Disease Research*, *3*(1), 12–18. https://doi.org/10.4103/0975-3583.91595

Singh, R., Chandel, S., Dey, D., Ghosh, A., Roy, S., Ravichandiran, V., & Ghosh, D. (2020). Epigenetic modification and therapeutic targets of diabetes mellitus. *Bioscience Reports*, *40*(9). https://doi.org/10.1042/BSR20202160

Singh, S., Kriti, M., K.S., A., Sarma, D. K., & Verma, V. (2024). Deciphering the complex interplay of risk factors in type 2 diabetes mellitus: A comprehensive review. *Metabolism Open*, *22*, 100287. https://doi.org/10.1016/j.metop.2024.100287

Sivri, D., & Akdevelioğlu, Y. (2025). Effect of Fatty Acids on Glucose Metabolism and Type 2 Diabetes. *Nutrition Reviews*, *83*(5), 897–907. https://doi.org/10.1093/nutrit/nuae165

Snel, M., Jonker, J. T., Schoones, J., Lamb, H., & de Roos, A. (2012). Ectopic Fat and Insulin Resistance: Pathophysiology and Effect of Diet and Lifestyle Interventions. *International Journal of Endocrinology*, *2012*, 1–18. https://doi.org/10.1155/2012/983814

Soriano-Pérez, L., Aranda-Rivera, A. K., Cruz-Gregorio, A., & Pedraza-Chaverri, J. (2022). Magnesium and type 2 diabetes mellitus: Clinical and molecular mechanisms. *Health Sciences Review*, *4*, 100043. https://doi.org/10.1016/j.hsr.2022.100043

Srivastava, A. K., & Mehdi, M. Z. (2005). Insulino-mimetic and anti-diabetic effects of vanadium compounds. *Diabetic Medicine*, *22*(1), 2–13. https://doi.org/10.1111/j.1464-5491.2004.01381.x

Stuart, C. A., Howell, M. E. A., Cartwright, B. M., McCurry, M. P., Lee, M. L., Ramsey, M. W., & Stone, M. H. (2014). Insulin resistance and muscle insulin receptor substrate-1 serine hyperphosphorylation. *Physiological Reports*, *2*(12), e12236. https://doi.org/10.14814/phy2.12236

Superti, F., & Russo, R. (2024). Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits. *Antioxidants*, *13*(10), 1228. https://doi.org/10.3390/antiox13101228

Talab, A. T., Abdollahzad, H., Nachvak, S. M., Pasdar, Y., Eghtesadi, S., & Izadi, A. (2020). Effects of Chromium Picolinate Supplementation on Cardiometabolic Biomarkers in Patients with Type 2 Diabetes Mellitus: a Randomized Clinical Trial. *Clinical Nutrition Research*, *9*(2), 97. https://doi.org/10.7762/cnr.2020.9.2.97

Tardif, N., Salles, J., Guillet, C., Tordjman, J., Reggio, S., & Walrand, S. (2014). Muscle ectopic fat deposition contributes to anabolic resistance in obese sarcopenic old rats through e <scp>IF</scp> 2α activation. *Aging Cell*, *13*(6), 1001–1011. https://doi.org/10.1111/acel.12263

Taylor, R. (2021a). Type 2 diabetes and remission: practical management guided by pathophysiology. *Journal of Internal Medicine*, *289*(6), 754–770. https://doi.org/10.1111/joim.13214

Taylor, R. (2021b). Type 2 diabetes and remission: practical management guided by pathophysiology. *Journal of Internal Medicine*, *289*(6), 754–770. https://doi.org/10.1111/joim.13214

Taylor, R. (2025). The Twin Cycle Hypothesis of type 2 diabetes aetiology: From concept to national NHS programme. *Experimental Physiology*, *110*(7), 984–991. https://doi.org/10.1113/EP092009

Taylor, R., Al-Mrabeh, A., & Sattar, N. (2019). Understanding the mechanisms of reversal of type 2 diabetes. *The Lancet Diabetes & Endocrinology*, *7*(9), 726–736. https://doi.org/10.1016/S2213-8587(19)30076-2

Thiyagarajan, G., Muthukumaran, P., Sarath Kumar, B., Muthusamy, V. S., & Lakshmi, B. S. (2016). Selective Inhibition of <scp>PTP</scp> 1B by Vitalboside A from *Syzygium cumini*

Enhances Insulin Sensitivity and Attenuates Lipid Accumulation Via Partial Agonism to <scp>PPAR</scp> *γ* : *In Vitro* and *In Silico* Investigation. *Chemical Biology & Drug Design*, *88*(2), 302–312. https://doi.org/10.1111/cbdd.12757

Turkmen, K. (2014). Sirtuins as novel players in the pathogenesis of diabetes mellitus. *World Journal of Diabetes*, *5*(6), 894. https://doi.org/10.4239/wjd.v5.i6.894

Vajdi, M., Noshadi, N., Bonyadian, A., Golpour-Hamedani, S., & Alipour, B. (2024). Therapeutic effect of fenugreek supplementation on type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. *Heliyon*, *10*(17), e36649. https://doi.org/10.1016/j.heliyon.2024.e36649

Venkatesh, U., Sharma, A., Ananthan, V. A., Subbiah, P., & Durga, R. (2021). Micronutrient's deficiency in India: a systematic review and meta-analysis. *Journal of Nutritional Science*, *10*, e110. https://doi.org/10.1017/jns.2021.102

VijayaKumar, A., Syed, I., Dhulipalla, H., Ghosh, P., & Srinivasan, L. v. (2025). Biofortification as a sustainable strategy to address micronutrient malnutrition in South Asia. *Journal of Health, Population and Nutrition*, *44*(1), 425. https://doi.org/10.1186/s41043-025-01108-6

Vijayakumar, M. V., Singh, S., Chhipa, R. R., & Bhat, M. K. (2005). The hypoglycaemic activity of fenugreek seed extract is mediated through the stimulation of an insulin signalling pathway. *British Journal of Pharmacology*, *146*(1), 41–48. https://doi.org/10.1038/sj.bjp.0706312

Vitola, B. E., Deivanayagam, S., Stein, R. I., Mohammed, B. S., Magkos, F., Kirk, E. P., & Klein, S. (2009). Weight Loss Reduces Liver Fat and Improves Hepatic and Skeletal Muscle Insulin Sensitivity in Obese Adolescents. *Obesity*, *17*(9), 1744–1748. https://doi.org/10.1038/oby.2009.171

Wiesmann, C., Barr, K. J., Kung, J., Zhu, J., Erlanson, D. A., & Shen, W. (2004). Allosteric inhibition of protein tyrosine phosphatase 1B. *Nature Structural & Molecular Biology*, *11*(8), 730–737. https://doi.org/10.1038/nsmb803

Wilcox, T., de Block, C., Schwartzbard, A. Z., & Newman, J. D. (2020). Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists. *Journal of the American College of Cardiology*, *75*(16), 1956–1974. https://doi.org/10.1016/j.jacc.2020.02.056

Xia, Q., Wu, F., Wu, W., Dong, H., Huang, Z., Xu, L., Lu, F., & Gong, J. (2022). Berberine reduces hepatic ceramide levels to improve insulin resistance in HFD-fed mice by inhibiting HIF-2α. *Biomedicine & Pharmacotherapy*, *150*, 112955. https://doi.org/10.1016/j.biopha.2022.112955

Xiang, F., Zhang, Z., Li, Y., Xia, B., Liao, Y., & Yang, C. (2025). Honokiol Targeting <scp>SIRT3</scp> : From Molecular Mechanisms to Therapeutic Opportunities. *The FASEB Journal*, *39*(13). https://doi.org/10.1096/fj.202501428R

Xu, R., Molenaar, A. J., Chen, Z., & Yuan, Y. (2025). Mode and Mechanism of Action of Omega-3 and Omega-6 Unsaturated Fatty Acids in Chronic Diseases. *Nutrients*, *17*(9), 1540. https://doi.org/10.3390/nu17091540

Xu, Z., Jin, J., Yang, T., Wang, Y., Huang, J., Pan, X., Frank, K., & Li, G. (2023). Outdoor light at night, genetic predisposition and type 2 diabetes mellitus: A prospective cohort study. *Environmental Research*, *219*, 115157. https://doi.org/10.1016/j.envres.2022.115157

Xun, H., Ma, L., Feng, B., & Ma, Y. (2025). Chromium Mitigates the Iron-Induced Glucose Metabolism Disorder via the PI3K/Akt/Bcl-2 Signaling Pathway: An In Vivo Study in Wistar Rats. *Biological Trace Element Research*. https://doi.org/10.1007/s12011-025-04867-9

Yang, Y., Li, W., Liu, Y., Li, Y., Gao, L., & Zhao, J. (2014). Alpha-lipoic acid attenuates insulin resistance and improves glucose metabolism in high fat diet-fed mice. *Acta Pharmacologica Sinica*, *35*(10), 1285–1292. https://doi.org/10.1038/aps.2014.64

Yu, Y., Ding, Y., Wang, S., & Jiang, L. (2025). Gut Microbiota Dysbiosis and Its Impact on Type 2 Diabetes: From Pathogenesis to Therapeutic Strategies. *Metabolites*, *15*(6), 397. https://doi.org/10.3390/metabo15060397

Zhao, Q., Zhang, T.-Y., Cheng, Y.-J., Ma, Y., Xu, Y.-K., Yang, J.-Q., & Zhou, Y.-J. (2021). Triglyceride-Glucose Index as a Surrogate Marker of Insulin Resistance for Predicting Cardiovascular Outcomes in Nondiabetic Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. *Journal of Atherosclerosis and Thrombosis*, *28*(11), 59840. https://doi.org/10.5551/jat.59840

Zheng, H., Xu, Y., Liehn, E. A., & Rusu, M. (2024). Vitamin C as Scavenger of Reactive Oxygen Species during Healing after Myocardial Infarction. *International Journal of Molecular Sciences*, *25*(6), 3114. https://doi.org/10.3390/ijms25063114

Zhuang, P., Mao, L., Wu, F., Wang, J., Jiao, J., & Zhang, Y. (2020). Cooking Oil Consumption Is Positively Associated with Risk of Type 2 Diabetes in a Chinese Nationwide Cohort Study. *The Journal of Nutrition*, *150*(7), 1799–1807. https://doi.org/10.1093/jn/nxaa103